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resumo 
 
 
Este relatório apresenta as atividades e projetos desenvolvidos durante o 
estágio curricular numa unidade de investigação clínica, o Laboratório de 
Farmacologia Clínica, parte do Instituto de Medicina Molecular. 
O estágio teve a duração de 10 meses, sendo que a atividade mais relevante 
foi a coordenação de ensaios clínicos na área de neurologia. Também 
colaborei em atividades de escrita científica, nomeadamente revisões 
sistemáticas em cardiologia, pediatria e farmacologia clínica. Tive ainda a 
oportunidade de participar na gestão de bases de dados clínicos, na 
monitorização e coordenação de estudos observacionais e em atividades de 
farmacovigilância. 
Refere-se, no estado da arte, o processo de Investigação e Desenvolvimento 
de novos medicamentos e são caracterizados alguns aspetos da investigação 
clínica em Portugal, nomeadamente o enquadramento da atividade, com 
enfoque na Neurologia. É ainda contextualizada a Farmacovigilância no atual 
sistema de avaliação da segurança dos medicamentos em Portugal.  
Este período de estágio possibilitou colocar em prática os conhecimentos que 
adquiri na Universidade, mas também expandi-los. Ao longo deste estágio, 
pude observar de perto dificuldades logísticas com que um centro de 
investigação se depara durante a condução de ensaios clínicos. Aprofundei 
também o conhecimento em investigação clínica, enquanto expandi as minhas 
áreas de interesse profissional. Pude melhorar as minhas capacidades de 
redação de documentos científicos, através da elaboração de várias revisões 
sistemáticas e meta-análises. Percebi também a importância das unidades de 
investigação clínica, bem como o papel fundamental dos coordenadores de 
ensaios clínicos na rigorosa execução de todos os procedimentos dos estudos 
e na comunicação entre os elementos da equipa. O treino específico centrou-
se em estudos clínicos, nomeadamente ensaios clínicos de fase II e III, e 
estudos observacionais em doenças neurodegenerativas. Apoiei a 
coordenação de quatro estudos em Polineuropatia Amiloidótica Familiar, dois 
em doença de Huntington, dois em doença de Parkinson, um em doença de 
Alzheimer e um em Distonia Cervical Idiopática. O contacto com os doentes foi 
parte muito importante da experiência em coordenação de ensaios clínicos.  
Considero que este estágio curricular foi uma experiência muito enriquecedora, 
onde comecei a executar atividades de investigação clínica. Desta forma, 
termino o estágio com motivação e interesse em trabalhar na área de 
coordenação de ensaios clínicos e gestão de projeto. 
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abstract 
 
This report presents the activities and projects developed during the curricular 
internship in a clinical research unit, the Laboratory of Clinical Pharmacology, 
part of the Institute of Molecular Medicine. 
The internship had a duration of 10 months, being that the most relevant 
activity was the coordination of clinical trials in the area of neurology. I also 
collaborated in medical writing activities, namely systematic reviews on 
cardiology, paediatrics and clinical pharmacology. I had also the opportunity to 
participate in the management of clinical databases, in the monitoring and 
coordination of observational studies and in pharmacovigilance activities. 
In the State-of-the-Art section is referred the process of Research and 
Development of new drugs and are characterized some aspects of clinical 
research in Portugal, namely the framework of the activity, with a focus in 
Neurology. Furthermore, the current context of Pharmacovigilance in the 
system of drug safety evaluation, in Portugal, is presented.  
This training period enabled me not only to put into practice the knowledge 
acquired at the University, but also expanding it. During this internship, I could 
closely observe the logistical difficulties that a research centre faces during the 
conduction of clinical trials. I also increased my knowledge in clinical research 
while expanding my areas of professional interest. I could improve my writing 
skills of scientific documents, through the elaboration of several systematic 
reviews and meta-analysis. I also realized the importance of clinical research 
units as well as the crucial role of clinical trial coordinators in the rigorous 
implementation of all the studies’ procedures and in the communication 
between team members. This specific training focused on clinical studies, 
namely phases II and III clinical trials and observational studies in 
neurodegenerative diseases. I supported the coordination of four studies in 
Familial Amyloidotic Polyneuropathy, two in Huntington's disease, two in 
Parkinson's disease, one in Alzheimer's disease and one in Idiopathic Cervical 
Dystonia. The contact with patients was a very important part of my experience 
in clinical trials coordination.  
I consider that this internship was a very enriching experience, where I started 
to perform clinical research activities. Thus, I finish the internship with 
motivation and interest to work in the area of clinical trials coordination and 
project management. 
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1. Introduction  
 
During the second year of my Master’s degree in Pharmaceutical Medicine at the 
University of Aveiro, which is affiliated to the PharmaTrain programme, I had the opportunity to 
carry out a curricular internship at the Laboratory of Clinical Pharmacology (LCP). LCP is an organic 
unit that belongs to the Institute of Molecular Medicine (IMM) and has its facilities in the Faculty 
of Medicine of the University of Lisbon (FMUL).  
This curricular internship lasted for about ten months, during which time I acquired 
knowledge and experience in four different sub-units – the Biostatistics and Methodological sub-
unit; the Outcomes sub-unit; the Safety and Drug Utilization Research sub-unit and the Clinical 
Trials sub-unit, which is focused mainly on neurodegenerative disorders. 
My training report, organized in five chapters, is the compilation of all the activities 
performed in the LCP and its functional sub-units. The first chapter is an introduction to 
contextualise the training and to present how it was structured. This introduction includes a 
characterisation of the host institution, the objectives defined for my internship and a description 
of the state-of-the-art on clinical research and clinical trials, namely their current regulatory and 
scientific framework in Portugal, as well as a reference to the pharmaceutical Research and 
Development (R&D) process. 
In the second chapter – “On the job training”- I described the activities and projects that I 
had the opportunity to develop during my internship and which enabled me to gain experience in 
various aspects of clinical research. I divided this chapter in two subchapters: specific training and 
generic training. Specific training comprises the activities of clinical studies’ coordination that I 
performed in LCP. Generic training corresponds to the data management, medical writing and 
Pharmacovigilance activities, as well as the training sessions, workshops and training courses 
performed during the internship.  
The third section, Discussion, presents the knowledge and lessons learnt during the 
training and if I achieved the proposed training objectives. The fourth chapter corresponds to the 
Conclusion, where I provide feedback about my experience, performance during the ten months 
of training, what it brought to my education, the positive aspects and what I would like to 
improve in the future.  
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1.1 Vision of the Host Institution  
My curricular internship was performed at the LCP, which belongs to IMM. LCP has 
functional sub-units: the Clinical Trials sub-unit of the Neurology Department from Hospital de 
Santa Maria - Centro Hospitalar Lisboa Norte (HSM-CHLN); Drug Evaluation and Systematic 
Reviews sub-unit, that corresponds to the Movement Disorders Cochrane Collaboration Review 
Group; the Safety and Drug Utilization Research sub-unit, where the Unidade de 
Farmacovigilância de Lisboa e Vale do Tejo (UFLVT) is located; the Outcomes sub-unit; the 
Biostatistics and Methodological sub-unit and the Pharmaco Magnetic Resonance Imaging (MRI) 
sub-unit (1, 2). 
IMM is an associate laboratory recognized for the biomedical research conducted there. 
Furthermore, IMM has established collaborative projects with HSM-CHLN and with several 
prestigious international institutions (3).  
This institution is located in the campus of FMUL and HSM-CHLN (3). IMM, FMUL and 
HSM-CHLN have recently formed the Centro Académico de Medicina de Lisboa, a consortium that 
is aiming to promote the academic dimension and edification in clinical practice, the 
modernization and development of research, medical education and innovation of health 
sciences. This aggregation renews the concept of teaching hospital and means to secure the 
essential compatibility of medical education with research and patient care, allowing the creation 
of start-up companies and multiple research collaborations (4). 
IMM is composed of several laboratories where researchers develop their projects. One 
of these units is the LCP, where I performed my curricular internship (3). 
 
1.1.1. Laboratory of Clinical Pharmacology  
Although LCP belongs to IMM, its facilities are located at FMUL and at the HSM-CHLN. 
HSM-CHLN is the largest hospital in Portugal, with several medical specialities and specialized 
services (5). In 2008, the fusion of HSM and Hospital Pulido Valente constituted the CHLN, a highly 
differentiated and distinguished institution, embedded in the Região de Saúde de Lisboa e Vale do 
Tejo.  CHLN is responsible for the direct provision of health care to 373 000 inhabitants. In 
addition to providing health services to the people living in Lisbon, these two hospitals also 
receive patients from all parts of Portugal and from abroad (5). 
The research team from the Neuropharmacology Unit of the Neurology Clinical Research 
Unit and the members of the Laboratory of Clinical Pharmacology and Therapeutics created LCP 
on July 2013 (6). Professor Joaquim Ferreira is now head of this laboratory. 
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The functional sub-units of LCP are represented in Figure 1. During its first year, the 
research team grew mainly with the arrival of new MSc and PhD students. The Drug Evaluation 
and Systematic Reviews sub-unit (Movement Disorders Cochrane Collaboration Review Group) 
was consolidated and the Safety and Drug Utilization Research Unit (UFVLT) gained sustainability 
with a revised service contract established with the National Authority of Medicines and Health 
Products - Autoridade Nacional do Medicamento e Produtos de Saúde, I.P. (INFARMED). After, a 
Biostatistics and Methodological sub-unit was developed and, more recently, a Pharmaco MRI 
sub-unit was created (Figure 1) (7). 
 
 
 
 
The main fields of interest for investigation in the LCP are clinical trials and the study of 
predictive biomarkers. It also provides services related to Clinical Pharmacology for research 
groups operating in HSM-CHLN, FMUL and IMM. In addition, it provides training in clinical trials 
conduction and Good Clinical Practices (GCP) and promotes collaborations with pharmaceutical 
companies and other research partners. The main research areas in LCP are neurodegenerative 
diseases, with a special focus on Alzheimer’s disease and Huntington’s disease; special 
populations, like paediatrics, rare diseases or late stage populations and “orphan” interventions. 
There is also an emphasis on outcomes research, development of systematic reviews and drug 
safety and utilization (1, 2). 
According to the most recent scientific report of IMM (7), in 2014, the LCP accomplished 5 
selected publications; had 6 ongoing research projects; 3 other important projects that started in 
2013; 39 publications in peer-reviewed journals; 20 invited lectures and seminars; 18 
communications in international conferences; 17 communications in national conferences; 
Figure 1 Structural organization of Laboratory of Clinical Pharmacology. Adapted from (1) 
UFLVT, Unidade de Farmacovigilância de Lisboa e Vale do Tejo; MRI, Magnetic Resonance Imaging. 
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participation in the organisation of 10 conferences; establishment of 2 research contracts with 
the industry ; 42 collaborations in advanced teaching; 7 collaboration works related to science 
and society and support in the execution of 8 MSc thesis (7). 
 
1.1.1.1. Unidade de Farmacovigilância de Lisboa e Vale do Tejo  
In my curricular internship, I had the opportunity to collaborate with the Safety and Drug 
Utilization Research sub-unit that corresponds to one of the four regional sections of the National 
Pharmacovigilance System - UFLVT. UFLVT’s activities cover the population of the Portuguese 
capital and areas in the vicinity that, according to the Lisbon and Tagus Valley Regional 
Administration’s activity report, corresponds to 3 659 868 inhabitants (8).  
This sub-unit is responsible for the collection, management, reception and processing of 
adverse drug reactions (ADR) obtained through several means: e-mail, letter and phone. UFLVT 
also generates safety alert signals-periodic safety update reports. Pharmacovigilance activities 
include report collection, validation and follow-up, data management and quality management of 
procedures, which allows competent authorities to act in order to ensure the quality and safety of 
commercialized medicines (9).  
UFLVT occupies a room inside the LCP facilities. Concerning physical resources, this room 
is equipped with material indispensable for the reception and processing of ADR notifications: 
three computers with access to internet, four secretaries, two phones, a scanner and a printer. 
One pharmacist and teaching assistant with qualifications in Pharmacovigilance, a Quality 
Manager and Pharmacovigilance technician and an administrative clerk compose the team that 
carries out UFLVT’s daily activities. Medical direction is the responsibility of an HSM-CHLN 
physician, who is a specialist in Neurology. The unit frequently receives trainees to gain 
experience in pharmacovigilance. 
 
1.1.1.2. Drug Evaluation and Systematic Reviews Sub-unit (Cochrane Review Group) 
Cochrane is a global network composed by collaborators who produce credible health 
information through systematic reviews (10). This high-quality information can be found and 
accessed from the Cochrane Library, for anyone who needs to take health decisions founded on 
evidence-based medicine (11). The LCP is part of the Movement Disorders Cochrane Collaboration 
Review Group, whose expertise is in the conduction of systematic reviews and clinical trial 
methodology issues (10). This sub-unit has one administrative person responsible for all the issues 
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related to Cochrane systematic reviews. LCP has a group of professionals that work with the 
Cochrane review group.  
 
1.1.1.3. Outcomes Sub-unit  
The Outcomes sub-unit is focused on the study of measurement instruments, including 
biomarkers and patient reported outcomes in drug evaluation. This sub-unit is headed by an MD, 
PhD who works at the HSM-CHLN and who is a specialist in Paediatrics. In this unit, he designs and 
develops observational studies, meta-analysis and other research projects with a focus on the 
paediatric population. This sub-unit is the chamber of the investigator, where the project 
meetings occurred. Hence, the collaborators of this paediatrician frequently work in the open 
space of LCP.  
 
1.1.1.4. Biostatistics and Methodological Sub-unit 
The Biostatistics and Methodological sub-unit provides support in the design, 
implementation, analysis and reporting of clinical research studies and in the optimization of 
study design and feasibility. The sub-unit works in a room and in the open space of the LCP. The 
room is equipped with four computers and a library of several books about clinical pharmacology 
and neurology. The open space has also a cabinet with books and journals, two computers and 
two printers. The projects are developed by a multidisciplinary team, with specializations in 
biostatistics, project management and medical writing.  
 
1.1.1.5. Clinical Trials Sub-unit 
The facilities of the Clinical Trials sub-unit are part of the Neurology Department from the 
HSM-CHLN. It is headed by Professor Joaquim Ferreira and, through his efforts, this unit became a 
part of the LCP (2). The activity of the clinical trials sub-unit has been particularly important for 
the clinical research performed at the LCP. In the beginning, the main research area was 
movement disorders and, as a result, the group gained the sub-name of Movement Disorders, 
focusing only in the conduction of clinical trials in this area. However, throughout the years, the 
group expanded its capacities and became able and qualified to conduct clinical trials in other 
neurological disorders. Today, the centre develops clinical studies essentially in Parkinson’s 
disease, Huntington’s disease, Familial Amyloidotic Polyneuropathy (FAP), dystonia, multiple 
sclerosis, and Alzheimer’s disease (2).  
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Patients have a central role in clinical research, and the proximity and attendance to 
potential participants increased since the Clinical Trials sub-unit is located in the Neurology 
Department. Potential candidates are identified in the outpatient clinic of the department. The 
execution of these clinical research projects also depends on the effort of an experienced 
multidisciplinary team that includes neurologists, psychiatrists, psychologists, nurses, speech 
therapists, study coordinators and other healthcare professionals. There is also a close link with 
the hospital pharmacy, namely the department of clinical trials, which is responsible for receiving, 
storing, and providing the drugs used in the clinical trials (12).  
A clinical research unit need structure to operate according to GCPs. The sub-unit has a 
room for participants’ examination, an office space equipped with computers, a room for the 
collection of biological material, a place to archive all the study’s documentation and materials 
and a room for clinical data monitoring. The sub-unit also has facilities for the processing and 
storage of biologic samples (refrigeration capacity -20 ˚C and -70 ˚C). Nowadays, the procedures 
of one of the clinical trials taking place in centre are performed on the seventh floor of the 
hospital, where the recently inaugurated Centro de Investigação Clínica do Centro Académico de 
Medicina de Lisboa (CIC-CAML) is located. The creation of CIC-CAML has the objective to facilitate 
the design and conduct of early phase clinical trials and proof of concept studies, giving support to 
clinical research in the University Hospital (13).  
 
1.1.1.6. Pharmaco Magnetic Resonance Imaging Sub-unit 
The Pharmaco MRI sub-unit is another asset of the LCP. The main objective of this sub-
unit is to develop projects in imagiology by magnetic resonance. In this sub-unit, neuroimaging 
techniques are used in the detection of micro-structural, functional and biochemical 
abnormalities in the central nervous system (7).  
 
 
1.2. Training Objectives 
I established some objectives to achieve with the execution of the different activities in 
the LCP and with the assistance of experienced health professionals. My primary objectives, which 
I defined a priori, are some skills that I consider critical to having a complete training on clinical 
research. I also defined secondary objectives throughout my internship, which relate to more 
specific skills and activities that I would like to accomplish, in order to complement my training. At 
the end of the training, I verified if I achieved my personal and professional goals. 
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1.2.1. Primary Objectives 
The primary objectives defined in my internship were: 
 To acquire knowledge, skills and qualifications in clinical studies’ coordination, including 
empirical knowledge about all the activities associated with them; 
 To understand the multidisciplinary character of a Clinical Research Unit and consequent 
development of certain personal, interpersonal and professional skills that will enable me 
to integrate the current labour market;  
 To acquire the basic knowledge and skills in clinical data management and extraction, 
including quality control procedures, as well as in the writing of scientific documents; 
 To understand the key concepts and procedures in pharmacovigilance and related areas 
of action in Portugal;  
 To obtain specific working tools and techniques through the contact with experienced 
professionals; 
 To apply and complement the theoretical background and skills acquired during the first 
year of my Master’s Course and through the Biomedical Sciences Degree. 
 
1.2.2. Secondary Objectives 
The secondary objectives defined in my internship were: 
 To prepare and support the conduction of clinical studies’ visits taking place in the clinical 
trials sub-unit, updating the documentation relating to each study; 
 To support the study team so as to comply with the protocol and all the processes 
associated with the clinical trials; 
 To acquire a comprehensive understanding of a clinical research project’s lifecycle; 
 To support and monitor the various projects taking place in the LCP during the internship; 
 To organize and manage clinical databases for statistical analysis; 
 To write a paper related to the area of clinical trials, improving my medical writing skills;  
 To be able to critically appraise the medical, scientific literature, including the 
methodology used in the elaboration of systematic reviews; 
 To participate actively in the daily activities of the UFLVT, including reception, validation 
and autonomous processing of spontaneous reports of ADRs; 
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 To develop and improve personal and soft skills, such as communication, self-confidence, 
critical thinking, problem solving, time management, organisation, autonomy and 
responsibility; 
 To identify potential areas of professional interest within the pharmaceutical industry and 
to establish a working contact network. 
 
 
1.3. State-of-the-Art - Clinical Research and Clinical Trials 
The pharmaceutical industry is nowadays the biggest investor in R&D (14). Clinical trials 
are part of R&D processes, constituting a set of advantages and benefits for stakeholders, which 
include the pharmaceutical industry, academic institutions and patients (14). The final goal of 
performing clinical trials is to test the effectiveness and safety of a new investigational medicinal 
product (IMP). However, the execution of clinical research has to assure that the rights, safety and 
well-being of participants are always protected (15). In this chapter, I will describe the current 
paradigm of the drug R&D process, the definition and different types of clinical trials, the process 
of implementation and conduction of clinical trials and the current position and hurdles faced by 
clinical trials and the pharmaceutical industry in the world and in Portugal.  
 
1.3.1. Overview of Pharmaceutical Research and Development Process 
The concept of clinical research covers the group of studies that involves humans, 
independent of their health status, or that uses the results of previous tests in humans as an 
object of study. It frequently appears related with pharmacological experimentation, conducted 
by the pharmaceutical industry or not (16). This patient-oriented research can include studies of 
mechanisms, therapies or interventions for human disease, studies to develop new medical 
technologies and clinical trials. Epidemiology and behavioural studies are also part of this concept, 
as well as outcomes and health services research (17). 
The purpose of discovering, developing and bringing to clinical use new medicinal 
products is to prolong or improve patients’ lives, by providing high quality health care (14). Its key 
contribution to global health is turning fundamental research into innovative treatments. The 
pharmaceutical industry and other stakeholders have been interested in minimizing the time and 
the cost needed to bring a compound from the scientific concept, through discovery and clinical 
development, to final regulatory approval and delivery to the patient. However, pharmaceutical 
R&D processes remain complex, time-consuming and very expensive (14, 18). 
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Some diseases like Alzheimer’s, cancer, diabetes and human immunodeficiency virus 
require much more research and expertise to identify novel treatment targets. In recent years, 
due to advances in scientific and technological methods, innovative and powerful research tools 
have been emerging, making medicines’ R&D more promising and challenging than before. As a 
result of the population’s increased needs and of the methodological progresses, investigators 
face a progressively demanding clinical and regulatory environment, which requires more 
extensive collaboration (14). The global pharmaceutical market is growing, with sales reaching US 
$1.08 trillion in 2011 (19). The mature economies demonstrated this growth in a very slow way, 
but the growing economies were another matter. If this pattern continues, the market for 
medicines could be worth nearly US $1.6 trillion by 2020 (Figure 2) (19).  
 
 
 
 
 
 
The pharmaceutical industry is the fifth largest industrial sector in Europe and accounted 
for 26.8% of the global pharmaceutical market in 2011, with an investment of €27.5 billion in R&D 
(20). According to the 2014 EU Industrial R&D Investment Scoreboard, the pharmaceuticals & 
biotechnology sector keeps the first position in the R&D ranking, maintaining a similar share of 
the total R&D investment (18.0%) (21). However, the combination of rising R&D costs, complex 
research areas, and regulatory requirements make the European Union (EU) a challenging 
Figure 2 The global pharmaceutical market in 2011 and the estimate in 2020. Adapted from (19) 
Growth markets: China, Brazil, Russia, India, Mexico, Turkey, Poland, Venezuela, Argentina, Indonesia, South Africa, 
Thailand, Romania, Egypt, Ukraine, Pakistan and Vietnam; EU-Big 5: France, Germany, Italy, Spain and United 
Kingdom. 
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environment for healthcare innovation. Only 4% or €50 billion of the total health expenditure 
corresponds to R&D, while the remaining 96% or €1.4 trillion is spent on healthcare (22). 
Therefore, the continuously declining productivity of the pharmaceutical industry makes an 
overhaul of the R&D model more important than ever. 
Companies often experience losses in terms of their R&D investments, because the high 
failure rates mark pharmaceutical R&D. Even if an early-phase compound seems to be promising, 
only preclinical and clinical trials will demonstrate its efficacy and safety. In addition, the later a 
failure occurs, the bigger may be the losses. A phase III failure is significantly more costly than a 
preclinical failure, because each phase is associated with a certain, compounded investment (23). 
Demand for pharmaceutical products is rising, as the global population increases, ages 
and becomes more sedentary (19). This more demanding reimbursement environment raises the 
bar for pharmaceutical innovation, making it essential to release innovative products. However, 
the replacement power of current pharmaceutical companies’ pipelines is compromised since the 
traditional fast follower and best-in-class strategies will not work anymore (24). Some progress 
has been made in recent years to address these challenges, including the adoption of an EU 
Regulation on clinical trials, an increase in the number of mergers, of licensing agreements and 
biotech acquisition of large biopharmaceutical companies, new research models coming to the 
fore that can make medicine development safer and more cost efficient (20). 
The private sector produces nearly all the medicines on the market. When a 
pharmaceutical company invests in the R&D of new medicines, it starts by screening chemical and 
biological compounds that exhibit the potential for treating new or existing conditions. R&D 
begins once researchers identify a promising compound among, on average, 5 000–10 000 
screened compounds (25). Researchers then extensively test the compound to ensure its efficacy 
and safety, a process that can take 10 to 15 years. It is a long, expensive and complex process, 
necessary to ensuring medicines meet the standards of quality, efficacy and safety (Figure 3). In 
2012, 43 new medicines were launched and currently more than 7 000 compounds are at 
different stages of development, globally. The difference in these numbers highlights the many 
research hurdles to be overcome before compounds can be developed into safe and effective 
medicines (25). 
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Figure 3 Pharmaceutical regulatory process. Adapted from (25) 
 
Setting up a drug discovery and development program requires careful planning. It is 
essential to identify the characteristics of the IMP in the early stages of development and to plan 
an appropriate development based on this profile. The discovery process includes the early 
phases of research, which are designed to identify an IMP and to perform initial tests in the 
laboratory. This first stage takes approximately 4 to 6 years (Figure 3). By the end, investigators 
hope to identify a promising drug candidate to further study in the laboratory, in animal models, 
and, finally, in people (26).  
The pre-clinical phase is dedicated to better understand the disease or condition in order 
to identify biological targets for a potential medicine and their role in disease. These studies are 
conducted in cells, tissues and animal models (25). 
After learning more about the underlying disease pathway and identifying potential 
targets, investigators then seek to narrow the field of compounds to one lead compound that 
could influence the target and, possibly, become a drug (25). They do this in a variety of ways, 
including creating a molecule from living or synthetic material, using high-throughput screening 
methods to select a few promising possibilities from among thousands of potential candidates, 
identifying compounds found in nature, and using biotechnology to genetically engineer living 
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systems to produce disease-fighting molecules. Most pharmaceutical companies spend a very 
small percentage of their budgets on target selection and validation (19). 
Even at this early stage of the research process, it is necessary to think about the final 
product, namely the route of administration, the formulation and the manufacturing process.  
Once one or more lead compounds are identified, pre-clinical tests are performed. Scientists carry 
out both in vitro and in vivo tests, using computer models, cells and animals. During this stage, 
scientists also must determine how to make large enough quantities of the drug to use in clinical 
trials. Techniques for making a drug on a small scale to use in this preclinical stage may not 
translate easily to larger production (25).  
R&D in the pharmaceutical industry is moving towards open innovation, embracing 
increased collaboration and sharing of knowledge. The Innovative Medicines Initiative is one 
example of this, as the largest European public-private partnership in biomedical research that 
brings together diverse stakeholders, including patient groups and investigators. The funding 
system is balanced 1:1 and the founding organisations of this entity are the European Federation 
of Pharmaceutical Industries and Associations and the European Commission. The central aims of 
the Innovative Medicines Initiative are to enhance safety and efficacy of therapies for the major 
diseases, as well as to improve knowledge management and education in R&D (20, 27).  
 
1.3.2. Clinical Trial Concept 
A clinical research study is an investigation that directly involves a particular person or a 
group of people or that uses materials from humans, such as their behaviour or samples of their 
tissues. The aims of these studies are to determine or confirm clinical, pharmacological or other 
pharmacodynamics effects of medical products, to identify any adverse reactions related to the 
IMP or to study the pharmacokinetic processes of one or more IMP. The final purpose is to 
establish their safety and/or efficacy profiles (28). 
Clinical studies may involve the study of a product that changes, influences or programs 
the health care, behaviour or knowledge of participants or caregivers, in order to discover or 
verify their health effects – interventional clinical study. On the other hand, participants may be 
part of interventions (which can include medical products such as drugs or devices) or procedures   
during their routine medical care – observational clinical study. All clinical studies, independently 
of the need of intervention or not, have to be designed, conducted, recorded and reported and its 
results revised and disclosed in accordance with the principles of GCP (29, 30). 
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A clinical trial is a type of interventional clinical study. The Randomized Controlled Trial 
(RCT) is considered the gold standard in terms of clinical trial design. As clinical trials are intended 
to discover or verify the security and efficacy of one or more IMPs, they are a long and careful 
process that may take many years to complete. Strictly following a pre-defined research protocol, 
the assignment of a subject to a particular therapeutic intervention is decided in advance and 
does not fall within normal clinical practice. The investigators also apply other diagnostic or 
monitoring procedures to the participants, in addition to normal clinical practice (29). 
Clinical trials may compare a new medical approach to a standard one that is already 
available, to a placebo, or to no intervention. When a new product or approach is being studied, it 
is not usually known whether it will be helpful, harmful, or no different from available alternatives 
(including no intervention). The assessments of safety and efficacy are performed by measuring 
certain outcomes. Clinical trials, compared to observational studies, are considered by many to be 
the reference method for evaluation of healthcare interventions (28, 30).  
The concept of clinical trial has also changed according to the events occurring in clinical 
research over the years. The concept of clinical trial began to be refined and adjusted with James 
Lind’s Scurvy Trial, in 1747 (31). This physician conducted a controlled trial on a ship to evaluate 
the most promising cure for scurvy. Lind chose twelve patients with similar manifestations of the 
disease and with one diet in common. Afterwards, he administered to each two of them, one of 
the alternative therapeutic regimens. At the end, Lind analysed the treatment that had produced 
the best results (31). In the 19th century, the concept of emerged, marking yet another important 
milestone in the history of modern clinical trials. The concept of randomization was introduced 
into clinical trials in 1923. Blind clinical trials, where neither group knows which treatment they 
are receiving, emerged when the first double blind comparative trial was performed to investigate 
patulin treatment for common cold. Multicentre clinical trials where multiple studies were 
conducted at various sites all using the same protocol to provide wider testing and better 
statistical data, were introduced, in 1946, when the first RCT of streptomycin in pulmonary 
tuberculosis was conducted (31).  
 
1.3.2.1. Ethical and Regulatory Framework 
Clinical research is a highly regulated area. All the activities related to the implementation 
and conduction of clinical trials follow ethical codes and important policies, directives and 
recommendations. The most important documents are the Declaration of Helsinki, the GCP of the 
International Conference on Harmonisation of Technical Requirements for Registration of 
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Pharmaceuticals for Human Use (ICH), the 2001/20/CE Directive, the 2005/28/CE Directive, and 
the 95/46/CE Directive. 
The biggest advances in protection for human subjects have been a response to human 
abuses. The World War II experiments were an example of unethical research. The Nuremberg 
Code appeared in 1947 and it was the first International Guidance on the ethics of medical 
research involving subjects. This document highlighted the importance of obtaining voluntary, 
informed consent from research participants. In 1948, the Universal Declaration of Human Rights 
expressed concern about the rights of human beings that were subjected to involuntary harm. 
The confrontation with the thalidomide disaster reinforced federal oversight of drug testing, 
including a requirement for informed consent (32). 
In 1964, in Helsinki, the World Medical Association articulated general principles and 
specific guidelines on the use of human subjects in medical research, creating the Declaration of 
Helsinki. The Declaration of Helsinki has been undergoing changes every few years. The last 
revision included increased protections for vulnerable populations, new provisions for research-
related injury compensations, and post-study requirements for reporting results to participants 
and providing access to any potential treatments that arise from the study. Despite not being a 
legally obligatory document, it is one of the most influential ethical guides in the history of human 
research (33).  
GCP has become the universal standard for ethical conduct of clinical trials. This guideline 
is valid in the EU, Japan and United States of America (USA) (15). For clinical research with medical 
devices in human subjects, the International Organization for Standardization (ISO) created the 
ISO 14155:2011. These international standards are transposed into legal requirements of laws and 
regulations by each national authority (34). 
Regulatory entities such as the European Medicines Agency (EMA) and the Food and Drug 
Administration, in the USA, are responsible for establishing procedures and rules for drug testing 
and for guaranteeing their implementation. In parallel to ethical guidelines, clinical trials started 
to become included in the legislation, with the aim of create an environment that was favourable 
for conducting clinical trials, with the highest standards of patient safety, for all EU member 
states. The 2001/20/EC Directive describes the requirements for the conduction of clinical trials 
with drugs for human use performed by the pharmaceutical industry and by academic institutions 
in EU. In 2004, this directive was transposed into the national legislation by Law No. 46/2004 of 
19th of August, which additionally established the Ethics Committee for Clinical Research - 
Comissão de Ética para a Investigação Clínica (CEIC) and was later repealed by a Law No. 21/2014 
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of 16th of April (35). Law No. 21/2014 – Clinical Research Law - covers all clinical research 
conducted in Portugal with humans, including not only clinical trials with IMPs for human use but 
also studies with medical devices, cosmetics, food supplements and observational studies. This 
law created the National Ethics Committees Network (coordinated by CEIC), a National Portal for 
the register of all clinical research, and a clinical trials database. This law was amended last year 
by Law No. 73/2015 of 27th of July that establishes the conditions under which the monitors, 
auditors and inspectors can access the records of clinical trials’ participants (29, 36). 
At the European level, Regulation No. 536/2014 of the European Parliament and of the 
Council of 16th of April, 2014, related to clinical trials of medicinal products for human use, was 
issued, repealing the 2001/20/EC Directive. This legislation will be directly applicable to the legal 
framework of the member states six months after publication in the Official Journal of the 
European Communities.  This publication is a notice of operational compliance of the Union portal 
and the EU database, emitted by the European Commission. This regulation shall apply only to 
events occurred after 28th May 2016 (35). 
The 2005/28/CE Directive lays the principles and guidelines for GCP as applicable to 
investigational medicines for human use, and the requirements for the authorisation of their 
manufacture and importation. This directive was transposed into the Portuguese Decree-Law No. 
102/2007 of 2nd of April. 
Another legislation to be observed is the 95/46/CE Directive on the protection of personal 
data, transposed to the Portuguese Law no. 67/98 of 26th of October and by the Deliberation No. 
333/2007 of the National Data Protection Authority - Comissão Nacional de Proteção de Dados 
(CNPD). 
Comparing to the USA, the EU presents the disadvantage of not having a European 
organisation for financing and promoting clinical research projects in the health area, as is the 
case of National Institute of Health (12, 37).  
 
1.3.2.2. Setting up and Running a Clinical Trial 
It can take up to 13 years to take a medicine from its origins as a molecule to a treatment 
with tangible benefits for patients (38). In this section, I will describe the steps needed to 
complete this process, which will help explain why it is so time-consuming.  
Drug development is ideally a logical, stepwise procedure in which information from small 
early studies is used to support and plan later, larger, more definitive studies, called clinical trials 
(38). When the truly development process is initiated, we can divide it in four temporal phases 
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(Phase I-IV). However, this classification provides an inadequate basis for classification of clinical 
trials because one type of trial may occur in several phases. According to the guideline ICH E8, a 
classification system using study objectives is preferable. The “phase” concept is a description, not 
a set of requirements. Thus, the temporal phases do not imply a fixed order of studies, since for 
some drugs in a development plan, the typical sequence will not be appropriate or necessary (26).  
 
Specifically, there are four temporal phases of development that correspond to the kind 
of studies usually performed: 
 Phase I (Human Pharmacology) – in this stage, the candidate drug is tested in people for 
the first time – first-in-man studies. Studies are usually conducted with a small number of 
healthy volunteers, generally from 20 to 100. The main goal of a Phase I trial is to assess 
the safety of the medicine in humans, determining the safe dosing range and if the 
candidate drug should move on to the next stage of development. The dose is gradually 
increased during this period to allow the investigator to measure the participant's clinical 
response to the drug (pharmacokinetics). They also study which dosage levels are safe 
and well tolerated (pharmacodynamics) (26). 
 
 Phase II (Therapeutic Exploratory) - investigators evaluate the candidate drug’s efficacy 
in about 100 to 500 patients with the disease. Initial therapeutic exploratory studies may 
use a variety of study designs. Many Phase II study patients receiving the drug compared 
with patients receiving a different treatment, either an inactive substance (placebo), or a 
different drug that is usually considered the standard of care for the disease. In this 
phase, researchers work to determine the most effective dosages and the best 
formulation, examining the possible short-term adverse events (AE) and risks associated 
with the drug. They also evaluate some potential study endpoints, therapeutic regimens 
and target populations. If the drug continues to show promise, it is prepared for the much 
larger Phase III trials (26). 
 
 Phase III (Therapeutic Confirmatory) – in this phase the potential drug is tested in about 
1000 to 5000 patients to generate statistically significant data about safety, effectiveness 
and the overall benefit-risk relationship. Phase III is used to test the results of earlier trials 
in larger populations and to demonstrate or confirm the therapeutic benefit. This phase 
generally provides the basis for the benefit-risk assessment for the new medicine and 
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much of the core instructions to help ensure proper use of the drug, like information on 
potential drug-drug interactions and specific dosing instructions (26). 
 
 Phase IV (Therapeutic Use) – in this period, all studies are performed after drug approval 
and are related to the approved indication. Despite these studies not being considered 
necessary for approval, they are often important for optimising the drug’s use through 
the assessment of long-term safety or effects in specific patient subgroups. They may be 
of any type but should have valid scientific objectives. Through these studies it is possible 
to collect additional information about drug-drug interaction, dose-response or safety 
(26). 
 
The rigorous planning and design of a clinical trial, taking into consideration certain key 
aspects, is crucial to generate meaningful results. It involves deciding parameters such as the 
patient population to be studied and the length of the trial, the treatment(s) to be investigated, 
taking into account current treatments, the outcomes and the methodologies by which the trial 
will be conducted (38).  
To be included in a clinical trial, patients must meet specific criteria (38). Among the 
common criteria are the existence of a particular disease or treatment history, and the fact that 
the participants belong to a certain age group (38). These eligibility criteria help ensure that the 
people in the trial are as similar as possible to each other, with respect to basic profile, type and 
stage of disease. It also ensures that the results of any treatment effect are associated as much as 
possible with the drug being studied, instead of other factors. Clinical trials are frequently 
controlled, that is, the agent or regimen being tested is compared with a control. This control may 
be either a medically ineffectual treatment known as a placebo (if no effective therapies are 
available for the disease being studied) or a standard treatment, that should be one widely used 
and with demonstrated effectivity at the time the trial was designed. Some trials take several 
years to complete and because of this, the standard treatment may no longer be the best 
available therapeutic choice (38).  
The aim of a clinical trial is to measure key outcomes and to test the clinical efficacy and 
tolerability of the treatment in a particular disease. The trial will usually specify a primary 
outcome, typically to assess the treatment efficacy. Usually, if that outcome is verified during the 
trial, it means a positive result for the study and the treatment being tested. A trial may also 
define one or more secondary outcomes, which normally include secondary efficacy measures 
and safety parameters.  The clinical trial protocol provides the design for the study conduct and 
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sets out the outcomes of the study. It explicitly states how and when to measure and evaluate 
these outcomes (38).  
In phase III and some phase II trials, the patient population may be randomized (randomly 
allocated to receive one or other of the alternative treatments being studied) and stratified 
(partitioned by a factor other than the treatment, often to ensure that equal numbers of 
participants with a characteristic thought to affect prognosis or response to the intervention will 
be allocated to each comparison group) (39).  
In practice, there are issues to take into count before starting a clinical trial (40). One of 
the first steps for running a clinical trial is the licensing approval. The investigators should compile 
the information and results from all the performed studies as well as a description of the 
medicine’s manufacturing process and submit this information to the regulatory agencies in order 
to demonstrate the safety and effectiveness of the new medicine. In order to perform clinical 
trials in Portugal, sponsors have to get authorization from the Competent Authority and ethical 
approval from CEIC plus approval from the CNPD. The application to the ethics committee, to the 
competent authority and to CNPD may be submitted in parallel, or in any order (40).  
During the approval process, there is no procedural interaction between the competent 
authority and the national or local research ethics committee (40). Nevertheless, all of them can 
request it. Once it has been concluded that a medicine is safe and effective, its value and cost-
effectiveness must be assessed. Health technology assessment processes are used by the relevant 
regulatory body to assess the added value of medicines and make decisions on access. Depending 
on the given healthcare system, health technology assessments can be used to determine pricing, 
reimbursement status, and/or prescription status (40). Once a drug is licensed for use and pricing 
and reimbursement measures determined, it may be made available for patients. Even after a 
drug is on the market, it is being scrutinized: post-approval or post-marketing studies are 
necessary to monitor a drug’s long-term effects (40). 
 
1.3.2.3. Clinical Trials in the World and in Portugal  
The clinical trials database – ClinicalTrials.gov - contains the registry of all clinical studies 
performed in the world. In 2000, the number of registered clinical trials was 5 634. On February of 
2016, the number of registered clinical trials is 208 114, with a growing trend observed over the 
years (41). The region with the biggest percentage of studies is North America (in particular the 
USA – 90 684 studies) followed by Europe (58 269 studies). Eighty percent are interventional 
studies, with the majority of them intended to test a drug or biologic product (41, 42).  
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In Europe, approximately 4 400 clinical trials are applied for, every year (43). However, 
Europe has been losing competitiveness comparing with other regions of the world (44). 
According to EudraCT, in 2015, approximately 80% of clinical trials were sponsored by the 
pharmaceutical industry and 20% by non-commercial sponsors. EudraCT is a database of all the 
interventional clinical trials with medicinal products in the EU, submitted to the ethics committee 
and competent authority, starting on the 1st of May, 2004 (Figure 4) (45). 
 
 
 
In the past, it was observed a decrease in the productivity and quality of clinical trials, in 
Portugal. According to INFARMED’s statistics, clinical trials in Portugal decreased in number 
between 2008 and 2011, with the number of submitted clinical trials went from 146 to 88 (Figure 
5)(46).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 Total of EudraCT Numbers each year in the EudraCT Database, from 2004 to 2015. Adapted from (45) 
Figure 5 Number and growth rate of clinical trials submitted in Portugal between 2008 and 2015. Adapted from 
(46) 
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This decline was due to several factors, like the lack of policies to promote clinical 
research in Portugal, the low number of infrastructures to perform clinical research in clinical 
centres and the devaluation of clinical research in medical curricula (12). However, in the last 
three years, this tendency seems to have changed, with 137 clinical trials submitted in 2015 (46).  
The majority of these studies are phase III clinical trials and the most explored therapeutic 
area is oncology, with the majority of drug candidates being antineoplastic and 
immunomodulating agents (Figure 6).  
 
  
 
 
 
 
 
 
 
 
 
 
The funding of clinical trials in Portugal is mainly in the hands of the pharmaceutical 
industry, which is complemented by a small number of non-commercial clinical trials (44).  
Neurology is one of the areas where the investment per participant is higher (44). 
Moreover, it is estimated that more than 600 disorders afflict the nervous system (47). 
Neurodegenerative diseases are hereditary and sporadic conditions, characterized by progressive 
nervous system dysfunction. These disorders are often associated with the atrophy of the 
affected central or peripheral structures of the nervous system and include diseases such as 
Alzheimer's disease and other dementias, genetic brain disorders, Parkinson's disease, Multiple 
Sclerosis, Amyotrophic Lateral Sclerosis, Huntington's disease, and others. In the last years, 
people have had access to better health care services, which increased the average life 
expectancy and to an aging population. The elderly are the age group with more incidences of 
dementia and other neurological diseases, which consequently affects their quality of life. Thus, it 
becomes indispensable to find new therapies and approaches to relieve symptoms (47).  
Figure 6 Percentage of clinical trials by therapeutic area, in 2015, in Portugal. Adapted from (46) 
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The Associação Portuguesa da Indústria Farmacêutica conducted a pilot study in 2012 
with the objective of quantifying the investment potential not used by Portugal, through an 
evaluation of pharmaceutical companies that performed clinical trials in our country. The 
preliminary results of this study showed that neurology was the clinical area with the second 
highest investment in clinical trials, surpassed only by oncology (44).  
  
22 
 
 
2. On the Job Training 
 
The “On the Job Training” section is dedicated to the presentation of the different 
activities that I performed during my internship. I will present two Gantt charts: one with a 
chronological sequence of my internship in the LCP sub-units and the other with the periods 
during which I collaborated in different clinical research activities. 
My internship can be divided into four phases that correspond to the periods during 
which I frequented the different LCP sub-units (Figure 7).  
 
 
Figure 7 Gantt chart with the schedule of my collaboration in the LCP sub-units. 
 
In the first phase, which marked the beginning of my internship (from September 2015 to 
November 2015) at the LCP, I worked mostly in data management and medical writing projects, in 
the areas of cardiology and clinical pharmacology. In the second part, which lasted two months, I 
developed projects at the Outcomes sub-unit, collaborating in the execution of meta-analysis and 
in project management and monitoring of an observational study in paediatrics. The third phase 
involved pharmacovigilance and drug safety quality control activities, developed at the UFLVT 
from January 2016 to March 2016. From March to the end of my internship, I had the opportunity 
to work as a study coordinator in several studies at the Clinical Trials sub unit. Despite this 
temporal division by different research activities, I remained active in medical writing and in other 
academia research projects during almost all the internship (Figure 8).  
Figure 8 Gantt chart with the activities developed during the internship. 
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2.1. Specific Training 
2.1.1. Clinical Trials Sub-unit Overview 
The last three months of my internship were spent at the Clinical Trials sub-unit. In this 
subsection, I will describe the specific experience acquired during this part of the training and all 
the activities that I performed, mainly as a study coordinator. The Clinical Trials sub-unit is 
dedicated to clinical research coordination, and to conducting clinical trials and non-
interventional studies, with a major focus on phase II and III clinical trials in neurodegenerative 
disorders.  
The activities performed at the Clinical trials sub-unit involve many stakeholders. Thus, to 
ensure data confidentiality, as well as the safety, rights and well-being of patients, during my 
internship I had to consider some guidelines and relevant legislation in clinical research, 
independently of the study involved. Since I generated data that was intended to be submitted to 
regulatory authorities, I understood that it was essential to follow all the regulatory requirements. 
During this time, I worked under the close guidance of two senior study coordinators, and 
alongside colleagues from my Master’s programme. 
In the first week of the internship, the experienced study coordinators gave me a full 
overview of the clinical site, the procedures in place and some points about the studies that I 
would coordinate more closely. I also learnt where the material was stored, and the general 
workflow of the centre, amongst many other aspects. Since I was in a completely new 
environment, I spent the majority of the first week asking questions related to the procedures, 
and receiving important feedback on my work. The hierarchical structure was also explained, as 
well as who the Principal Investigator (PI) and the Clinical Research Associates (CRA) of each trial 
were. Every team member had very specific roles, which I had to become acquainted with. Some 
of the studies that took place in the unit were initiated after my training began, others were 
completed during the training, and others were finished earlier. Thus, I did not closely accompany 
all these studies.  
Throughout the internship, I received training in areas and procedures that are common 
to almost all clinical trials. These include: the compliance with the procedures stated in the 
protocol, the measurement of vital signs, the processing of laboratory samples and the filling of 
electronic Case Report Forms (eCRFs). Despite this and to facilitate the work in the centre, I was 
allocated to specific studies, and, for this reason, I worked full time with particular neurologic 
conditions: FAP, Huntington’s disease and Parkinson’s disease. Answering to queries and 
questions about the clinical trial and organizing the studies’ documents are examples of specific 
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activities that I was responsible for. Despite the majority of them being clinical trials, I also 
followed the conduction of two observational studies. A summary of the clinical trials and the 
observational studies that I participated in as a coordinator is presented on Table 1. 
 
Table 1 Clinical studies that I coordinated more actively in Clinical Trials sub-unit.  
Study designation Phase Condition Study design Intervention 
ALN-TTR02-004 Phase 3 FAP Double blind Patisiran 
ALN-TTR02-006 
Extension 
phase 
FAP Open label Patisiran 
ISIS CS2 Phase 3 FAP Double-blind IONIS-TTR Rx 
ISIS CS3 
Extension 
phase 
FAP Open-label IONIS-TTR Rx 
LEGATO-HD Phase 2 
Hungtinton’s 
disease 
Double-blind Laquinimod 
DUODOPA Phase 2 
Parkinson’s 
disease 
Open label Duodopa 
ACADIA Phase 3 
Parkinson’s 
disease psychosis 
Double-blind Pimavanserin 
ENGAGE Phase 3 
Alzheimer’s 
disease 
Double-blind Aducanumab 
INTEREST Observational 
Idiopatic Cervical 
Dystonia 
Prospective 
Cohort 
Botulinum toxin 
type A 
REGISTRY Observational 
Huntington’s 
disease 
Prospective 
Cohort 
- 
FAP, Familial Amyloidotic Polyneuropathy 
 
Because of the frequency of the study procedures in the site, there were two studies 
where I participated more actively, both about FAP, which I will detail below. 
 
 ALN-TTR02 
ALN-TTR02-004 (APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for 
the Treatment of Transthyretin (TTR)-Mediated Amyloidosis) is a phase III, multicenter, 
randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of 
patisiran in subjects with FAP. This study, sponsored by Alnylam Pharmaceuticals, is currently 
ongoing, having recruited 225 participants of several countries, aged 18 -85 years, of both 
genders and with a diagnosis of FAP. These participants were randomized to receive either 
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patisiran or placebo, which have been administered by intravenous infusion. In TTR02-004, the 
administration of patisiran or placebo occurs every 3 weeks for up to 18 months (48, 49).  
ALN-TTR02-006 (The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the 
Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been 
Treated With ALN-TTR02 (Patisiran)) is a multicenter, open-label, extension study to evaluate the 
long-term safety and efficacy of patisiran in patients with FAP who have completed a prior clinical 
study with patisiran and meet certain eligibility criteria, namely having completed the last efficacy 
visit in the parent study (ALN-TTR02-004) and, in the opinion of the investigator, tolerated study 
drug. In this extension phase, approximately 228 participants, that will receive patisiran 
administered by intravenous infusion, are expected to be recruited (49, 50). 
 
 ISIS 420915 
ISIS 420915-CS2 (Efficacy and Safety of IONIS-TTR Rx in FAP) is a phase II/III, randomized, 
double-blind, placebo-controlled clinical trial. It aims to assess the efficacy and safety of ISIS 
420915 in subjects with FAP. This study is sponsored by Ionis Pharmaceuticals, Inc. and recruited 
172 participants with early to mid-stage neuropathy, aged 18 and 82 years, of both genders. To be 
included in this clinical trial, the subjects had to be in late stage 1 or early stage 2 of the disease. 
Patients received either IONIS-TTR Rx or placebo for 65 weeks. IMP or placebo were administered 
subcutaneously 3 times on alternate days in the first week and then once-weekly for 64 weeks 
(51).  
ISIS 420915-CS3 (Open-Label Extension Assessing Long Term Safety and Efficacy of IONIS-
TTR Rx in FAP) is an open-label extension study, that is now recruiting patients who satisfactorily 
completed the dosing and efficacy assessments in ISIS 420915-CS2. It aims to assess the long-term 
safety and efficacy of ISIS 420915 in patients with FAP. IONIS-TTR Rx is administered once weekly 
(52, 53).  
 
Beside the above-mentioned studies, I also participated in other interventional and 
observational studies (Table 1). However, most of them required less visits and involved simpler 
procedures. In the observational studies, the principal coordination activities were to provide the 
patient’s dossier to the investigator and enter data into the CRF. 
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2.1.2. General Procedures in Clinical Trials Sub-unit 
 
 Compliance management 
Compliance with the study protocol is imperative, because it helps to ensure that the 
collected results are accurate and scientifically rigorous. During my training in study coordination, 
it was necessary for me to be acquainted with the protocol, including knowing the study 
objectives, proceedings and timelines, eligibility criteria, data confidentiality and participants’ 
protection rules. Once I understood the protocols, I was able to collaborate in the visit procedures 
of several clinical trials. After the investigators find a potential candidate and the patient is 
included in the study, according to the protocol procedures, the patient could have to visit the 
site according to the protocol’s assessment schedule. Thus, I received training in scheduling the 
study visits with the patient or with his caregiver, taking into consideration the timelines required 
by the protocol and the participant’s availability. These routine visits were frequently scheduled 
either by the investigator, or by the study coordinator. For each visit, I was instructed to read 
what the protocol required, and prepare in accordance with the sponsor’s and authorities’ 
standards.  
 
 Measurement of vital signs 
Although the measurement of vital signs is not an official task of a study coordinator, this 
is a characteristic procedure of all studies in some of their schedule visits. Since I accompanied 
participants during their entire visit period in the centre, I was authorized to measure and register 
vital signs. This included the assessment of blood pressure, pulse, temperature and respiratory 
rate. This procedure was frequently done in the beginning of the visit, before the participant was 
observed by the other research members that did other procedures. The training I received 
allowed me to do these simple procedures and collect this data when the protocol required it. 
 
 Processing of laboratory samples 
Each clinical trial had a laboratory manual, providing instructions on how to collect, 
handle, process, and ship the required biological samples. Human biological samples are all 
biological material of human origin, which includes organs, tissues, and bodily fluids like blood 
and its derivatives (54).  
The collection of laboratory samples was a mandatory procedure of almost all clinical 
trials, since the data provided through the analysis of these samples is an important source of 
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information for the continuity of the study. Frequently, the participant is required to cooperate 
with the collection of urine and blood during site visits, with the intervention of an experienced 
laboratory technician for the collection of blood. After that, the participant gives the urine and/or 
blood samples to the study coordinator that processes them according to the laboratory manual 
of the correspondent study. This usually means allowing some time to pass for the blood to clot, 
and then centrifuging the tubes. After centrifugation is complete, the plasma is transferred to the 
transfer tubes. The central laboratory of each trial provided a custom requisition and all the 
equipment necessary for storing and sending the biological samples. As a study coordinator 
trainee, I had to ensure the correct labelling, temperature-controlled stability, packaging and 
delivery of human biologic samples in order to obtain quality data of periodic safety assessments.  
The shipping of samples was done either in ambient temperature or in dry ice. For visits 
that required samples to be sent in dry ice, I usually requested them in advance, as to arrive at the 
same day of the visit. Once the shipment was ready, I called the courier services to schedule the 
pick-up. After the samples arrive to the laboratory, the results are provided. Because the 
collection of biologic samples must comply with ethical and transparency codes, the participant 
had to give informed consent for the collection of his or her biologic samples and to be informed 
about the potential future use of the samples and about the dissemination of research results 
(54).  
 
 Organizing documentation 
As a study coordinator, I was also responsible for the organization and management of the 
studies’ documentation. In this sub-unit, each study had a specific cabinet, where its documents 
were safely archived and properly organized. However, the basic features were similar for all 
studies, like the participants’ dossiers and the Investigator Site File (ISF), where all information 
concerning the clinical trial is available, including the study protocol, contact information, 
financial agreements, and study manuals, among others. In these cabinets, we also kept some 
specific study equipment like tablets, dossiers with scales and other necessary documentation for 
the visits. During my internship, I understood the importance of organizing all the documents and 
materials related with the study. The validation of the procedures required per protocol involves 
the reporting of that data in a physical and electronic support. The information could go missing if 
these supports were lost or not well organized; it is a risk for the quality and viability of the study.  
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 e-CRF filling  
Case Report Form (CRF) is a specialized document, where all data of each clinical trial 
participant have to be recorded. It should be study protocol driven, robust in content and it has to 
easily allow the entry of data. Despite paper CRFs still being used, electronic CRFs offer certain 
advantages, such as the improvement of data quality, online discrepancy management and faster 
database lock. At the Clinical Trials sub-unit, all studies had eCRFs. 
There were specific eCRF platforms for each clinical trial, such that I had to learn how to 
manage different types of eCRFs. The site study coordinators taught me how to access each eCRF 
and to entry the data as well as to validate, correct and answer queries, according to GCP. I could 
work with the following electronic systems: InformTM, BioClinica®, ViedocTM, and OracleTM. 
In addition, I received training about the systems responsible for IMP allocation and 
prescription. Some clinical trials had Interactive Voice Response System (IVRS) and other 
Interactive Web Response System (IWRS), and I learnt how to use both. The importance of data 
confidentiality when accessing the different eCRFs was also made clear during the initial training.  
 
2.1.3. Clinical Studies’ Specific Activities 
  After my initial training in these general activities of coordination, I started being part of 
the specific activities in place at the centre. The initial training was essential so I could do an 
efficient job in the clinical trial specific activities, such as preparing patient appointments and 
answering queries. While each trial is different, there were many procedures common to all of 
them. I will describe some of the more specific, trial-related activities I did. 
 
 Feasibility Phase 
The feasibility phase is one of the first steps in clinical trial conduction and it is composed 
by a set of site visits and contacts, with the objective of ensuring that the clinical site meets all the 
necessary requisites to carry out the clinical trial. The sponsor contacts the PI, in order to 
understand his interest in conducting the study. Then, a feasibility questionnaire is sent with the 
objective of evaluating the clinical research site conditions and PI availability. The PI and the study 
coordinators schedule a meeting to fill it in, where the main characteristics, challenges and 
requirements of the study are also discussed. 
By filling in this questionnaire, the PI should provide some specific information, which 
includes data about the site’s experience in clinical research, the target disease, resources and 
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facilities available, and who the person of contact is, in case of additional questions. After all this 
information is sent back to the sponsor, the site waits for a feedback. If the sponsor/Clinical 
Research Organization (CRO) agrees on the implementation of the study at the site, a face-to-face 
feasibility visit is scheduled. During this visit, the PI, a study coordinator, and sometimes the 
pharmacy staff, must be available. The sponsor/CRO usually requests a tour of the facility and 
time to discuss the basic elements of the protocol and how these are related to the feasibility of 
recruiting potential participants. 
In this pre-study visit the PI responsibilities are usually discussed; the necessary 
qualifications of study team members; the study objectives and outcomes; the procedures 
required in the protocol; the eligibility criteria, and patient recruitment strategies; ethic issues, 
like the approval timelines from the Administration Board of the HSM-CHLN and from the Ethics 
Committee; AE reporting; source documentation, and record retention. In this phase the space 
requirements, availability of a secure area to store IMP or devices and the availability of required 
equipment are also assessed. During my training, some feasibility meetings occurred in the unit. 
Although I did not participate actively in any, I consider that it is an important topic to understand 
the study implementation route. 
 
 Investigators’ Meeting 
The investigators’ meetings are appointments with the purpose of training the members 
involved in the conduction of the clinical trial on all aspects of the protocol. The study team 
members required to be present this meeting usually include the monitor/CRA, the PI, co-the 
Investigators, the study coordinator(s), the health technicians, and the quality managers. They 
receive training on GCP, the study protocol, the required procedures, and how to manage 
correctly the study equipment and software. The members present can ask questions and make 
comments during the meeting. I did not attend any investigators’ meeting because I was a trainee 
and only the principal study coordinators were authorised to participate. Sometimes this meeting 
counts as the initiation visit, meaning that when the study members return to the site, they are 
ready to screen their first subject. However, I will describe in the next topic a site initiation visit as 
a separate step.  
 
 Site Initiation Visit 
The site initiation visit is crucial because it is the last step before the sponsor activates the 
study side for enrolment. After the clinical site facilities are evaluated and qualified, all regulatory 
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requirements have been completed, the Ethics Committee approval obtained and the 
investigators have been enlightened about the clinical trial, it is necessary to schedule a meeting 
between the sponsor, the CRA and the study team. Thus, all the elements involved in the clinical 
trial receive adequate training from the sponsor/CRO. This meeting involves an explanation about 
the study rationale, distribution of study material and discussion of some important issues, 
procedures and screening schedules. It is also the opportunity for the sponsor/CRO to ensure that 
the investigator fully understands his or her responsibilities. The monitor usually visits the 
infrastructures of the site and verifies if any extra equipment is needed. The main preoccupation 
is to ensure the good condition of the pharmacy, and the equipment to process and store the 
biological samples. 
During my internship, I had the opportunity to attend one site initiation visit, wherein the 
sponsor and the CRA explained the clinical trial to study team.  
 
Some topics discussed during the site initiation visit included: 
 Investigator’s Brochure; 
 Study Protocol;  
 Clinical trial design; 
 Inclusion and Exclusion Criteria; 
 Informed Consent Form (ICF); 
 IMP characteristics and handling requirements; 
 AE and Serious Adverse Events (SAE) and its reports;  
 ISF; 
 CRF; 
 Source documents; 
 Delegation Log; 
 Central Laboratory; 
 Pharmacy conditions; 
 Monitoring Requirements; 
 Complementary Exams; 
 
It was also an opportunity for the research team to ask questions concerning the trial. 
After the presentation was concluded, I provided help to my coordinator colleagues and to the 
CRA, by organizing and archiving the study documents, seeing if the delegation log was properly 
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signed, requesting signatures and curricula of some members of the research team that could not 
attend the site initiation visit and collecting some equipment certificates.  
 
 Preparing Study Visits 
When the clinical trials were ongoing, it was the study coordinator’s responsibility to 
conduct them according to the timelines and procedures described in the protocol. Each 
participant’s dossier had a schedule with the time window for each visit; the study coordinator’s 
function was to schedule these visits according to the participants’ and study team members’ 
availability. However, it was important that the period established by the sponsor for each visit 
was not exceeded, so as to avoid a protocol deviation.  
A good preparation of the study visits was essential because that decreased the 
probability of error, and the anxiety of the team, while increasing self-reliance. This preparation 
included reading the protocol procedures corresponding to the specific visit for that participant, 
as well as the preparation of the material that should be available for that visit. All necessary 
information was in the protocol, frequently presented in tables.  
Most visits required a diversified evaluation, such as a clinical evaluation, vital signs’ 
assessment, psychological assessments, samples’ collection, electrocardiogram and quality of life 
questionnaires. Obviously, there were several professionals involved in one single visit and 
because of that, a previous organisation is fundamental. A day or two before the visit, I pulled all 
the required material for the visit from the study cabinet, like the patient’s medical file, the 
source documentation, IVRS or IWRS sheets, vital signs form and pharmacy prescription forms. I 
also labelled the laboratory tubes, when necessary. 
Some important topics will be explained below in order to better understand the 
differences between study visits. 
 
First visit 
The presentation and explanation of the ICF mark significantly the first visit to the clinical 
site. The PI delivers a copy of this form to the participant, giving him or her the opportunity to 
read and think about the study. After that, another contact is scheduled to know about the 
patient’s decision and discuss any doubts that may exist. If the patient agrees to participate in the 
study, the screening procedures are initiated. 
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Screening Visit and Baseline/Randomisation Visit 
A screening visit happens if the patient agrees to participate in the study. In this type of 
visit, I supported the investigator in any doubt about the ICF, the protocol and informed the 
patients about our availability in helping them with any situation related to the clinical trial. 
The screening visit was the first step for the participation of the patient in the study. 
Between this visit and the baseline visit several complementary exams were frequently required 
in order to confirm if the individual was apt to participate. I had to schedule these exams, 
organise the transportation and inform the participants. After that, if the exams’ results were 
favourable, I scheduled a baseline/randomisation visit.  
In the baseline/randomisation visit, some auxiliary evaluations were performed and the 
IMP was delivered. It was explained to the participants and to their caregivers how to take the 
IMP and any special precautions to take. Sometimes the patient did not meet the eligibility 
criteria to enter the study and, in these cases, the participants were deemed as a screening 
failure. During my internship, I witnessed several screening failures, frequently with patients that 
had to carry out psychological scales and were in an early stage of the disease. The research team 
rescreened some of these patients once the conditions that prevented them from participating. 
  
Regular Visits  
During my internship, I was responsible for contacting the study participants a few days 
before the scheduled day for the visit, in order to guarantee their attendance and ensure they had 
not experienced an ADR between visits.  
Generally, to prepare a regular visit I looked at the tables presented in the protocol, 
verified which procedures had to be performed and collected the necessary documents from the 
cabinet, organising them. I prepared the patient´s medical record, IVRS/IWRS worksheets, 
laboratory kits and requisition forms, vital signs record form, the worksheet to schedule the 
complementary exams, and the requisition to order dry ice, when applicable.  
Some clinical trials had specific worksheets for each visit, with the procedures to be 
performed. We registered the data collected during the visit in these worksheets. These checklists 
were usually delivered by the sponsor/CRO and I considered them important for our internal 
organization and assurance of correct data collection. In those cases where the checklists were 
not provided, I created them, in order to organize all the procedures and tasks of clinical trials in 
which I was involved. 
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In some studies, patients took the medication at home and when they came to the clinical 
site, I received the IMP and returned it to the hospital pharmacy, but always after checking it and 
verifying the patient’s treatment compliance. I also checked the medication that the participant 
would need between the site visits and requested it to the pharmacy. When a collection of 
biological samples, vital signs, electrocardiogram and administration of psychological scales were 
necessary, I provided support and performed some of these procedures.  
ICF amendments throughout the study were common, due to information being changed, 
added or removed from the protocol. Even if these were small changes, the study coordinator 
was required to instruct the investigator to sign and date a new ICF and the participants were 
informed about the changes. 
Sometimes the participants suffered AEs. In these cases, a more detailed assessment was 
required and only then did the investigator decide what should be done. In certain cases, when 
the condition was doubtful, the PI contacted the CRA to discuss the condition with the sponsor. 
When the health situation was not favourable to allow the patient to continue in the clinical trial, 
the PI advised the patient to leave the study, and an early termination was performed. I witnessed 
one early termination situation, where I was responsible for contacting the participant in order to 
ask if he wanted to continue the study but he refused it. Due to this, it was considered an early 
termination and the patient later performed a follow-up visit. 
The completion of IVRS or IWRS allowed to conclude the process concerning the 
prescription of medication. I performed these under the supervision of the site study 
coordinators. In visits when the IMP was dispensed, I filled the pharmacy prescription form with 
the medication lot number, signed and dated by the investigator, and then I sent it to the 
pharmacy through e-mail. When the IMP arrived at the Department of Neurology, the investigator 
registered the lot number and the identification number on the subject’s process. The IMP was 
delivered to the patient, and the patient received instructions on how to take it. I also explained 
the details on the next appointment. In some clinical trials, the medication was only administered 
at the clinical site through infusion.  
After all this process, I verified the patient’s expenses and carried out the necessary 
reimbursements.  
 
 
 
 
  
34 
 
After the Visit 
After the visit, I reviewed all source documents to ensure that all necessary data were 
collected and were consistent. I introduced the data in the eCRF. Usually, after this procedure, 
some queries would appear. Prompt resolution of queries was of maximum importance. The 
simple ones, like data entry errors, were quick to solve, but the ones that were more complex, like 
the ones related to inconsistences or incoherencies required a team effort amongst investigators 
and coordinators to be solved.  
If an electrocardiogram was done on a given visit, I would send it to the central laboratory 
for evaluation. I also verified the SAEs and AEs reports and their respective follow-up. Finally, I 
archived all the documents and used material in the patient’s folder in their respective division of 
the archive room.  
 
 Monitoring Visits 
The role of the monitor/CRA is critical for the development of the clinical trial. The 
monitoring visits are visits that the CRA undertakes at the study site to verify the compliance of 
the collected data with the study’s protocol. Firstly, the monitor/CRA contacts the site (via email 
or phone) to schedule the visit according to the PI’s, co-investigators’ and study coordinators’ 
availability. After finding a compatible date, the monitor/CRA went to the centre. Days before the 
visit, I organized the participants’ dossiers, solved queries and reviewed pending issues from the 
last monitoring visits. When the monitor arrived at the centre, he or she verified all source 
documents and I helped him or her to read the patients’ records and to find specific information. 
After this, the monitor met the PI and the study coordinators to clarify further doubts. 
 
 Close-out Visit 
The close-out visit occur after the last patient visit, when the site has already finished the 
recruitment period and all patients have completed their last visit. All CRFs and documents must 
be updated and completed with no queries left open. At this moment, the sponsor can close out 
the clinical trial at the site. I helped the group to answer queries and update some documents. 
After that, the essential study documents stayed at the site until further instructions from the 
sponsor. Usually, the next step was the archiving of the clinical trial documents in the archive 
department of the HSM-CHLN. 
 
 
  
35 
 
 Archiving documents 
I also assisted in the organization of the physical space of the unit. After the clinical trials’ 
close-out visits, the documents should be archived during at least 15 years after the end of the 
study, according to national legislation (15). After the sponsor’s authorisation and after contacting 
the central archive of the HSM-CHLN, I helped to store the essential documentation in boxes and 
to take them to the central hospital’s archive. The boxes should be properly identified in case they 
need to be consulted posteriorly. To facilitate the identification of the boxes, we made labels with 
the name and number of clinical trial protocol, PI identification, sponsor identification, and when 
applicable, the CRO’s address and contact. 
 
 Other activities 
During my internship in Clinical Trials sub-unit I also performed other activities. I regularly 
contacted the study monitor in order to clarify any doubts or how to procedure in particular 
situation or how to resolve some queries. This contact happened through e-mail, telephone and 
sometimes face-to-face. Because the CRA was the bridge between the clinical centre and the 
sponsor, he/she was always close to the research group. This strict communication avoided 
protocol violations. I also had to be in touch with external clinicians, central group and company 
of transport. This situation was due to the fact that sponsors/CRO made contracts with other 
entities to perform the complementary exams.  
I also archived documents and performed some activities of quality management. 
Specifically, in order to ensure the proper conditions of the material I verified the validation date 
of the material used, such as laboratory kits, and if anything was missing. 
To ensure a good conduction of the patients’ visits, every Friday the study coordinator 
organised a timetable with all the visits and important events in the unit and sent this document 
by e-mail to all members involved, like PIs, laboratory technician, pharmacists, ratters, nurses and 
other team elements. 
Clinical trials sub-unit is placed in Neurology department. Therefore, we frequently 
collaborate in the packaging and shipping of blood samples that came from the Day Hospital. We 
were going to get the patients’ samples properly identified, we pack them in adequate kits and we 
called the carrier.  Complementary to the main activities I usually did the download of the 
temperature recorded by freezer temperature logs once a week.  
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2.2. Generic Training 
The following sections describe the activities that I consider more generic, each divided by 
the sub-units I have worked at. 
 
2.2.1. Activities at the Biostatistics and Methodological Sub-unit 
For the first two months of my internship, I worked at the Biostatistics and 
Methodological sub-unit, where I mainly performed medical writing and clinical data 
management activities. During the first two weeks, I was introduced to the activities that were 
performed at the LCP, by reading some dossiers with the reports of the scientific projects 
submitted to national and international institutions. The principal research areas are 
neurodegenerative pathologies, with studies about pharmacologic and non-pharmacologic 
therapeutic approaches. Besides the statistical analysis of clinical data, the sub-unit gives support 
in writing tasks for the submission of applications for funding and in the final editing of 
manuscripts that are submitted for publication. With the end of this introductory period, I was 
given the chance to work in several medical writing and clinical data management projects.  
Medical writing is a set of activities with the purpose of communicating with rigor new 
scientific information to different audiences. These activities require clear understanding of the 
medical concepts and ideas, and an ability to present the data and their interpretation in a way 
the target audience will understand. This implies the use of an appropriate language and 
adaptation of technical terms’ use to the audience. Moreover, the writing needs to meet the 
specific requirements of the different types of documents, and it is now an important function in 
the pharmaceutical industry (55, 56). 
 
2.2.1.1. Medical Writing and Data Management 
To contextualize my activities as medical writer and data manager, I will provide in the 
following paragraphs a brief overview of what is a systematic review and a meta-analysis. Then, I 
will detail the activities that I performed in this context, since all the projects I was involved in at 
this sub-unit were systematic reviews and meta-analysis, except the first one.  
Systematic reviews and meta-analysis are a key element of the current evidence-based 
healthcare, followed by RCTs, in terms of  “ranking of evidence”(57). Evidence-based medicine 
integrates individual clinical expertise with the best available external clinical evidence from 
systematic research (58). A systematic review is a type of review article. A review article can be 
defined as a scientific text that results from a constructive analysis of previously published 
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literature or data about a specific topic (58). This results in a stand-alone publication, structured 
with a title, an informative abstract; an introduction; a chapter with material, methods and 
results; a discussion; a conclusion and the references (57). 
A review earns the adjective systematic if it is based on some essential premises. It results 
of a clear, previously formulated research question, followed by the identification, selection and 
assessment of the relevant literature’s quality and a synthesis of all the relevant articles on a 
given topic (57). Thus, the result of a systematic review is a summary of the best available 
evidence relevant to the research question that will allow it to be answered (57). This summary of 
the information is performed by use of explicit procedures, namely strict statistical analysis. 
Frequently, a systematic review includes a meta-analysis component, where statistical techniques 
are used to synthesize the data of all included studies into a single quantitative estimate or 
summary effect size. These are particularly helpful for different studies with contradictory results. 
Pooling the results into a single, unified result, can often lead to findings of significant clinical 
importance, with some systematic reviews leading to significant changes in clinical practice. 
Systematic reviews have a broader and more explicit approach that allows the minimization of 
bias, possessing many advantages over traditional reviews (57, 58).  
 
2.2.1.1.1. Cardiology projects 
In October, I met a cardiologist intern and PhD student that collaborated with the LCP. He 
suggested that I collaborated with him in some of his research projects, related to cardiology 
topics.  
Despite most of this physician’s publications being systematic reviews and meta-analysis, 
the first project that he proposed to me was retrospective, observational, pharmacovigilance 
study. The objective was to assess all oral anticoagulant-related spontaneous notifications of AEs 
in the last 5 years reported to the Portuguese Pharmacovigilance Database. Initially, he presented 
a pharmacovigilance database with spontaneous reports of ADR related to the use of new oral 
anticoagulants (NOACs) available on the Portuguese market. INFARMED provided this database 
and because I was not an expert in cardiology and did not have practical experience in 
pharmacovigilance, the investigator started with a contextualization of the current prescription of 
NOACs in Portugal and the importance of the use of these drugs in the treatment of certain 
prothrombotic conditions. I was responsible for the classification of each ADR present in the 
database and for its analysis according to the Preferred Term, the System Organ Class and 
suspected anticoagulant drug. For this classification, I had to learn about the use of the Medical 
  
38 
 
Dictionary for Regulatory Activities (MedDRa), an important tool in pharmacovigilance and drug 
safety monitoring. Thrombotic and bleeding events are relevant outcomes in patients under 
vitamin K antagonists or NOAC treatment. Thus, they are distributed across the different System 
Organ Class and consequently along broad terms of the Standardised MedDRA Queries. 
After data management, I built several tables and graphics for the presentation of results 
and discussed them with the physician. I contributed to the writing of every section of the article, 
with important contributions and orientations of this professional, especially in the discussion 
section. This paper was submitted to a national publication of the clinical area with the title: 
Adverse drug reactions with oral anticoagulants in Portugal: data from the national 
pharmacovigilance database of spontaneous reports. 
 
After this, I collaborate again with this cardiologist in the execution of a systematic review 
and meta-analysis about the security of NOACs. The underlying assumption of the study was the 
assessment of the coronary risks of NOACs based on findings from placebo-controlled trials. We 
performed a meta-analysis that included results from both interventional trials and observational 
studies. Although I had an active role only on the screening of some observational studies that 
were included, in data extraction and in the presentation of results through several tables, this 
collaboration was important to me because it was my first contact with the real execution of a 
systematic review and meta-analysis. Until then, I knew the steps necessary for the execution of a 
systematic review, but I never had to put them in practice.  
The physician explained me some important concepts, including the interpretation of the 
data that was collected and statistically analysed through Review Manager (RevMan®), a software 
for conducting meta-analysis. The article, entitled: “Safety of non-vitamin K antagonist oral 
anticoagulants - coronary risks”, was accepted on March of 2016 for publication in the journal 
Expert Opinion on Drug Safety (Impact factor – 2.911). 
 
At the same time, I collaborated in other cardiology systematic review with meta-analysis 
about the use of NOACs in elderly patients with atrial fibrillation. It was important to study the 
use of certain medications, like NOACs, in special populations. We reviewed and quantified, 
through the meta-analysis of RCTs, the efficacy and safety parameters of NOACs in the elderly 
population, in comparison with their impact in younger patients. We searched in MEDLINE, 
Cochrane Library, SciELO collection and Web of Science databases. Two authors reviewed the 
trials and calculated the risk ratios using a random effects model. I collaborated in data extraction 
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and in the writing of some parts of the article. I also participated in the preparation of tables for 
the presentation of results. The article, with the title “Non-vitamin K antagonist oral 
anticoagulants in elderly patients with atrial fibrillation: a systematic review with meta-analysis”, 
was submitted.  
 
When I finished my internship at Statistics and Methodological sub-unit, I continued to 
collaborate with this cardiologist on his projects. The following project was a systematic review 
and meta-analysis with the aim of evaluating the risk of cardiovascular events related to coffee 
consumption in patients with previous myocardial infarction. The investigator proposed the topic 
and it interested me very much because I always thought about the cardiovascular consequences 
of coffee consumption and this was an opportunity to find some published evidence about this 
topic. It also seemed interesting to study a beverage consumed worldwide and its association 
with a medical condition that causes several comorbidities. After this, my colleague and I 
established a protocol with the steps to perform the systematic review - PICOS. With the help of 
RevMan guidance, we defined our objectives and all the topics necessary to do this paper. After 
establishing the research protocol, we discussed it with the physician and defined a research 
strategy to be used in the PubMed/MEDLINE database. After researching all available information 
about the topic, we performed the screening of the articles, taking into account our final 
objectives. Using Covidence, we imported the citations from MEDLINE and screened them, 
independently. Posteriorly, we extracted the full texts of the selected articles and performed a full 
text review in the same platform. Covidence is a web-based software platform recommended by 
Cochrane that improves the production of systematic reviews (59). After we screened the articles, 
we extracted the study characteristics and other study data, building the tables for the 
presentation of results. After a critical analysis, data were exported into the relevant RevMan 
tables or spreadsheets, so the meta-analysis could be performed. I also collaborated in the writing 
of some parts of the paper, like the introduction, the materials and methods and the results.  
 
2.2.1.1.2. Clinical Pharmacology Project 
Two weeks after I had started my internship at the Statistical and Methodological sub-
unit, Professor Joaquim Ferreira challenged me to work with him in a subject that he wanted to 
explore – Clinical Pharmacology teaching. Because our laboratory was clearly associated to this 
discipline and most of the professionals that work at the LCP teach Clinical Pharmacology and 
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Therapeutics to FMUL students, it seemed to be an important issue to explore. Afterwards, we 
discussed the objectives of our project and the better approach to perform it.  
Professor Joaquim Ferreira was interested in doing a systematic review of all the available 
evidence about the teaching of clinical pharmacology in medical schools all over the world, 
namely a presentation and examination of the different curricula for undergraduate students, the 
years when the discipline was taught, the duration of the courses, the teaching methodologies 
used, the core skills and the programs’ contents, if these were mandatory or elective courses, if a 
student formulary was done, if the curricula included classes with patient interaction and, finally, 
the methodologies for the assessment of the students’ performance. Professor Joaquim Ferreira 
and I established a search strategy that I applied to the Pubmed/MEDLINE database. I imported 
the available citations from PubMed to a reference management software (EndNote), eliminated 
duplicates and screened the articles. After I had the bibliography library, I started to extract the 
data from papers and organizing it in an Excel sheet. It was a difficult task because the available 
information was heterogeneous, even inside the same country and the published data were 
presented in different ways. Because there was not a standard presentation of the data, I had to 
adapt my methodologies for its collection as I read the articles. During this time, Professor 
Joaquim Ferreira gave me tips to better perform data extraction and management. After a 
consensus about the available information, I was responsible for presenting the results (tables 
and graphics) and writing the article, with the supervision and revision of Professor Joaquim 
Ferreira.  
 
2.2.2. Activities in the Outcomes Sub-unit  
During about one month and a half, I had the opportunity to collaborate in various 
activities of the Outcomes sub-unit, whose principal responsible is a MD, PhD, paediatrician at the 
HSM-CHLN and a member of the LCP. 
 
2.2.2.1. Observational Study Monitoring - ALFABETO  
The main project I participated in was ALFABETO - ALto Fluxo – Antever na Bronquiolite a 
Eficácia Terapêutica e Outcomes. ALFABETO was an observational, pilot, prospective study. Its 
primary objective was to identify, in an exploratory way, the demographic, clinical and 
physiological prognostic factors responsible for the success/failure of high flow nasal cannula 
oxygen therapy in paediatric acute bronchiolitis. When I started to collaborate with the PI, this 
multicentre study had three clinical centres with all documents approved and ready to receive the 
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study – HSM-CHLN; Hospital Beatriz Ângelo and Hospital Fernando da Fonseca. However, Hospital 
Garcia de Orta was also interested in taking part in this project. Thereupon, my first tasks were to 
update and to adjust the study orientation documents, the ICF, study protocol, CRF and the 
archiving dossiers in order to provide all the necessary tools for the participation of Hospital 
Garcia de Orta. When all legal authorizations were obtained from the site, the study was ready to 
be implemented and the patients could start to be recruited in all centres. I was responsible for 
the project management activities, always following GCP and the procedures described in the 
study protocol. 
  ALFABETO was a pilot study and the centres involved did not have enough experience in 
high flow oxygen therapy. Thus, I prepared and updated some educational material for the health 
care professionals to start becoming familiar with the equipment and study procedures. This 
material included equipment orientation documents, USB drives with tutorials and study 
contents, and dossiers with the study information for each centre.  
When the first participants that were eligible for the study were included and received 
the high flow oxygen therapy, I started to perform study-monitoring activities. I optimized and 
adapted the previously elaborated study databases. I also received the paper CRFs from the 
centres and entered the information in the databases. At that time, as the study monitor, I was 
also checking the validity of the available data and making queries, in order to improve the quality 
of the entered data and to solve some mistakes in the filling of the CRF. During this process, I 
periodically wrote a newsletter to make the team aware of the status of the study. These 
newsletters included some important topics that the investigator and I considered important to 
clarify to the other study elements. These points could be some recurrent queries that I detected 
in the CRF or some procedures that could require special attention and standardization in order to 
increase data quality. I also had the responsibility to alert a co-investigator of our centre for the 
parents’ contact, as described per protocol. It was also my function to collaborate with the PI in 
raising awareness with the research teams and to contact with other centres in order to clarify 
some doubts about the filling of the CRF. During this time, I also did some logistic tasks, such as 
counting, organizing and registering the study material available at the Department of Paediatrics 
of the HSM. 
 
2.2.2.2. Academic Project – Outcomes in Paediatrics 
In parallel with the project management activities of the previous observational study, I 
collaborated in an academic project whose supervisor was the previously mentioned investigator. 
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This project, with a focus on Paediatric investigation, was the final dissertation of a FMUL medical 
student.  
It was a systematic review of the scientific articles about acute diseases in paediatrics, 
namely, acute bronchiolitis. This review had the primary objectives of assessing the prevalence of 
exclusion criteria in clinical trials of paediatric acute conditions, evaluate, and describe the 
hospital related outcomes. I participated in the discussion and in the establishment of a PICOS for 
this project, according with its main objectives. Afterwards, with the help of another investigator, 
we established a search strategy based on the eligibility criteria of the study – RCT; paediatric 
populations (<18 years); the existence of a chronic condition (acute bronchiolitis-as defined by the 
study authors); treatment and in any language. After we had created the search strategy, we 
tested it on the Cochrane database to search for systematic reviews. These systematic reviews 
were used as the primary source of information. Posteriorly, we created a list of the clinical trials 
that were included on these systematic reviews. After this systematization of the information, it 
was necessary to screen the systematic reviews and the clinical trials that fit our purpose. We 
created two Endnote libraries to archive our search: one for the systematic reviews and another 
for the clinical trials.  
I was responsible for the elaboration of a data collection key, an instrument that could be 
used by three independent investigators. This helps by standardizing the data collection for the 
studies’ and, consequently, the project’s quality. It helped to analyse the functionality of the Excel 
sheet previously elaborated. Then, we extracted all the important data according to our 
objectives. These data, presented in tables, were following analysed and graphics and tables were 
created to show our results. I also collaborated in this process. This systematic review, entitled: 
“Children with Chronic Diseases in Pediatric Clinical Trials”, was present to FMUL as the final 
project of the Master’s Degree in Medicine. After I finished my internship at the Outcomes Sub-
unit, I continued to work in the elaboration of this systematic review. 
 
2.2.3. Activities in the Safety and Drug Utilisation Research Sub-Unit  
When competent authorities approve a drug, it can be commercialised. However, a 
continuous verification of its effects in the general population is necessary. According to the 
World Health Organization (WHO), pharmacovigilance is the science relating to the detection, 
assessment, understanding and prevention of the adverse effects of medicines. 
Internationally, the Pharmacovigilance system is connected to the Vigibase, a worldwide 
database of ADRs, which is continuously updated and maintained by the Uppsala Monitoring 
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Centre, and the EMA database, the Eudravigilance Data Base Management System, where ADRs 
related to medicinal products marketed in the EU are recorded. 
Since 2000, the Pharmacovigilance system gained a new structure, with the creation of 
regional centres responsible for collecting spontaneous ADR reports from healthcare 
professionals. Patient spontaneous reporting has also been available in Portugal since 2012, when 
the new pharmacovigilance legislation came into force. This has increased the number of 
spontaneous ADR notifications (60). At the moment, there are four regional pharmacovigilance 
units. These centres cover the entire region of Portugal, playing a key role in encouraging the 
reporting of ADRs, involving universities to promote their scientific and technical expertise and in 
spreading the system (61).  
My collaboration at the UFLVT started in January and lasted two months. The first two 
weeks were an introductory phase to Pharmacovigilance concepts and procedures. During the 
rest of the time, I developed activities related to drug safety monitoring.  
The introductory phase started with a brief oral explanation by a Quality Manager and 
Pharmacovigilance Technician about the main purposes of the UFLVT and the activities developed 
to reach their objectives. After that, I read some related scientific literature and guidance, for 
instance, the book “Farmacovigilância em Portugal” (62). I also learnt about the context of 
pharmacovigilance in the current regulatory framework by reading the Good Pharmacovigilance 
Practices guidelines. I also had the opportunity to get to know the Quality Management System 
(QMS) and access the QMS documentation (quality manual, processes, operational procedures, 
work instructions, document templates and records). The QMS was implemented in the UFLVT 
three years ago, in order to harmonize the procedures, with the final objective of minimizing 
errors and increasing the quality of results. I read other dossiers that allowed me to understand 
the structure of the UFLVT and the functions of each collaborator, as well as the interaction with 
the competent authority-INFARMED.  
After the initial training, I was able to collaborate in the daily activities of the UFLVT. The 
daily responsibilities of the unit included the collection, management, and assessment of 
medicines’ safety data. This assessment could result in the detection of abnormalities in the data 
that should be reported, through safety warning signs based on the evidence of ADRs. I started to 
learn how to receive and validate notifications that came through different ways. When the unit 
received a spontaneous ADR notification, it could arrive by e-mail, telephone, fax or mail. UFLVT 
had specific formularies to collect the notification data, depending on the entity that made the 
notification. Sometimes I filled these sheets with information received by telephone. A suspected 
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ADR may be notified to the Marketing Authorisation Holder of the suspected drug, directly to 
INFARMED, or to the Regional Unit of the notifier’s area of activity or residence. The notification 
process became simpler because users and health professionals started to submit their ADR 
notifications through electronic submission in Portal RAM.  
One of my first tasks at the UFLVT was to learn the four minimum requisites to validate an 
ADR notification: identification about the notifier; identification about the patient; the suspected 
active substance; and a signal or symptom of an ADR. If the report was considered valid, the 
notification was assessed. After this validation, the notification was dated, signed and a number 
code was assigned. In order to confirm the existence of the notifier and to collect additional 
information to write the initial report, the professionals of the UFLVT contacted the notifier 
directly. I performed these additional information requests, when they were necessary. 
Subsequently, the notification data, which should be as complete as possible, was inserted in the 
SVIG and a copy of the original report provided by the notifier was attached. A reply was sent to 
the notifier confirming data had been received and its report had been accepted. When we 
entered the notification data in SVIG, we had to search for duplicates, in order to assure that the 
report did not yet exist in the on-line system. Then, we inserted some relevant demographic 
information about the patient, as well as his or her pharmacologic and clinical history. Data about 
the notifier, the ADR and the suspected drug were also necessary. While the notifications were 
being processed, it was necessary to check if the reported reaction was already described in the 
Summary of Product Characteristics of the suspected drug or in the available literature, because 
this influenced the final assessment of the notification.  
To enter the information characterizing the ADR, it was necessary to use MedDRA, an 
important, medical terminology tool for ADR classification. This terminology was developed by 
the ICH, with the goal of standardizing, at the national and international level, the classification 
system of ADRs. Most of the information was entered in summary form, but this can be 
supplemented with narrative information, including notifier’s comments. The entry of data on 
SVIG was communicated to the Pharmacovigilance department of INFARMED and a specific code 
for the notification was generated.  All of the cases reported nationally are filed in SVIG’s national 
database. Later, this information is shared with the EMA and the WHO, allowing its analysis in 
broader contexts.  
The medical coordinator of the unit, neurologist and member of the Committee for 
Medicinal Products for Human Use - EMA, assessed the notifications, in order to assign the proper 
causality category, which was posteriorly added to the notification’s SVIG record. According  to 
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the Uppsala Monitoring Centre, the causality of an ADR can be classified as follows: certain, 
probable/likely, possible, unlikely, conditional/unclassified, or unassessable/unclassifiable (63). 
During my internship, I prepared several documents with all the notification data, in order for the 
medical director to attribute the causality. 
Afterwards, a summary report about the case, as well as all the important information 
and details necessary to understand it, was written. This report was attached to the original 
notification and archived in the UFLVT. During my internship, I frequently did narratives of some 
notifications that were posteriorly verified by the UFLVT experienced collaborators. 
Depending on the outcome and severity of the ADR, the notifier can be contacted by the 
UFLVT in order to update and follow-up the case until the case is considered finalised. The notifier 
was afterwards informed about the causality classification attributed to the notified suspect ADR, 
and if any decision related to the medicine was made based on the spontaneous notification.  A 
warning sign, resulting from a quality or efficacy problem detected in the notification, may be 
generated. These cases had to be assessed by the clinical coordinator and, after a decision had 
been made, a report was sent to the Direction of Inspection and Licensing, so that the case could 
be followed. 
In the last weeks of my internship at the UFLVT, I attended the first meetings about the 
implementation of a clinical trials pharmacovigilance system. I did some research in the guidelines 
and legislation currently in force. This type of systems must be in place to enable the 
identification, recording, reporting and analysis of safety information so that any safety signals 
that arise during a trial are quickly identified and acted upon. I also took part in a meeting with 
the UFLVT professionals for the discussion of some important aspects in UFLVT’s activities that 
should be improved and of the achievement of UFLVT’s objectives, as well as for the planning of 
future projects, strategies and educational courses. 
By the end of the internship, I was able to perform autonomously some of these daily 
activities of the unit. I could verify that every person in this sub-unit was responsible for a 
separate set of tasks, in sequence, with the workflow resembling an assembly line. First, the ADR 
notification was received. A time limit was set on the calendar for completing the coding, 
recording the AE, and conducting the follow-up process. 
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2.2.4. Other Activities 
 
 Good Clinical Practices Course 
On December 4th, 2015, I attended the GCP course organized by the LCP. Because the 
complying with the GCPs is essential to perform clinical research with quality and rigor, the 
knowledge of GCP concepts and practical rules is mandatory for everyone who wants to do 
investigation with human beings. The LCP professionals, with extensive background in these 
topics, presented the several themes discussed during the course. It started with an introduction 
to the GCP principles, followed by a regulatory framework. The importance and content of the 
study protocol were also covered, as well as the study’s essential documents. The responsibilities 
and roles of the stakeholders in a clinical study were explained, as well as the pharmacovigilance 
in clinical trials. Finally, some practical aspects to take into account during the conduction of 
clinical studies were discussed. During the entire course, the speakers gave space for questions 
and discussion.  
 
 Pharmacovigilance Course 
From the 16th to the 19th of November, I attended an intensive course on 
Pharmacovigilance, in the facilities of the HSM-CHLN and organized by the UFLVT. The course 
provided an overview on the different mechanisms of ADR spontaneous notification, the 
importance of performing risk-benefit assessments, pharmacoepidemiologic studies and causality 
assessment of ADR. The course also provided an overview of the National Pharmacovigilance 
System. The course then gave a rundown of the most common AEs notified for the main 
anatomical groups.  
 
 Wednesday Meetings 
Every two weeks, on Wednesday afternoons, a meeting on the LCP was held with all 
members of the team. In these meetings, projects in areas like clinical pharmacology, cardiology 
and neurology were presented. The majority of these presentations were performed by LCP’s 
members and were about projects that they were working on. This helped the team members get 
to know what everyone was working on, discuss the project or an idea for a project, provide 
feedback and opinions, or just show the results of their labour.  
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 Journal Club 
The Journal Club meetings happened every Wednesday mornings and took place in the 
Neurology Department, where the Clinical Trials sub-unit is located. These meetings were 
composed by neurologists and by other health professionals that collaborate with the LCP and the 
Neurology department of the HSM-CHLN. Each week, one member of the team was assigned to 
bring a recent article in the field of neurology and neurosciences. The article was explained to the 
rest of the team, with a description of the methodologies and the study’s findings. After that, 
there was space for discussion, usually about the design of the study, the potential therapeutic 
applications of the findings, the pertinence of the article on the actual reality of medicine, 
amongst other relevant topics. Besides the presentation of recent scientific papers, these 
meetings also included video sessions, with the presentation of some clinical cases related to 
specific neurologic conditions, which were important to share with other health professionals. In 
these meetings, the research projects of some team members were also presented.  
 
 Internal Workshop: Assessment of Risk of Bias Tool 
The assessment risk of bias tool is an important instrument used to evaluate the quality of 
a systematic review and meta-analysis. Since part of my internship at the LCP was spent 
collaborating in the execution of systematic reviews and meta-analysis, I participated in a 
workshop presented by a member of the Cochrane group and LCP, that was focused on the 
explanation of this recommended approach for assessing risk of bias in studies included in 
Cochrane reviews. Two parts compose this tool. Each domain in the tool includes one or more 
specific entries in a ‘risk of bias’ table. Within each entry, the first part of the tool describes what 
was reported to have happened in the study, in sufficient detail to support a judgement about the 
risk of bias. The second part of the tool assesses the risk of bias for that topic. This is achieved by 
assigning a judgement of ‘low risk’ of bias, ‘high risk’ of bias, or ‘unclear risk’ of bias. In the end, a 
quality score is attributed to the systematic review.  
 
 Data Entry 
I collaborated with a LCP member in the process of data entry. This data corresponded to 
results from a validation study of a scale for Parkinson’s disease - Movement Disorder Society- 
Unified Parkinson’s Disease Rating Scale. I entered the data from the CRFs into a computer system 
database, in this case, Excel. It was indispensable to confirm the correct introduction of results 
with the help of independent investigators. 
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3. Discussion 
 
During this training, I had the opportunity to understand more about the practice of 
clinical research  not only through the support given in the conduction of clinical trials and 
observational studies, but also through the participation in several medical writing projects and in 
pharmacovigilance activities, thereby contributing to further scientific progress. These ten months 
were full of experiences, constant knowledge and hard work. Little things and situations that, 
overall, enriched my training and improved some personal and professional skills followed the 
major projects and activities that I previously described.  
A multidisciplinary team collaborates in the various sub-units that compose the LCP, the 
host institution. The projects developed allowed the exploration of several approaches related to 
clinical research and clinical pharmacology. Thus, the opportunity of doing an internship at the 
LCP was clearly a very enriching experience in these areas. I had the opportunity to work in these 
different research departments, do several activities, learn with senior professionals and be in 
contact with patients. Although I have been mainly involved in the coordination activities of 
several clinical studies, I also gave support to physicians in their academic research projects, 
developing and preparing papers about current themes in clinical research, monitoring an 
observational study in paediatrics and following the daily activities of a pharmacovigilance 
regional unit.  
The Clinical Trials sub-unit is a very well organised centre composed of experienced and 
qualified professionals and all the procedures are performed in compliance with protocol 
requirements, ethical guidances and regulatory guidelines. During my internship, I realized how 
difficult it is to conduct a clinical study, since it involves several health professionals with 
particular functions.  It is of maximum importance to maintain everyone focused, aware of each 
other’s roles and of the study objectives. I learnt about the several hurdles that have to be 
overcome during the conduction of a clinical trial and which frequently discouraged team 
members. However, it was gratifying to see the resilience and the constant search for solutions, 
to solve any problems that arose. This strategy had the intention to produce quality data and 
transform the Clinical Trials sub-unit into a reference centre. 
My experience as study coordinator trainee made me realize the key role of this class of 
health professionals in clinical trials. From the beginning to the end of the clinical trial, the study 
coordinator manages the operational aspects of medical research studies, being responsible for 
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ensuring that the research team strictly follows the protocol procedures, which requires high 
organizational skills. Entering data on the study’s CRF platforms, as well as assisting the 
monitors/CRA, are also responsibilities of the study coordinator. Since we contacted directly with 
study participants, it was necessary to develop communication skills, in order to be able to 
manage their anxieties and expectations, but at the same time to be efficient and scientifically 
rigorous in the transmission of information to investigators, monitors and other team members. 
This contact and consequent collaboration between study coordinator and all research team 
members happens during the study submission and coordination. I had to adapt my discourse to 
the patients, according to scientific requirements. Initially, I had some difficulties, but with time, I 
learned how to deal with them. I had to learn what information I could transmit and how I could 
do it. Another point that I needed to improve was how to manage my feelings. Sometimes it was 
difficult to maintain the distance between me, as a health professional, and the patient. Over 
time, I developed strategies to overcome this difficulty.  
When I started my training at the Clinical Trials sub-unit, I had some difficulties. It was 
necessary to understand the sequence of procedures and tasks needed for each study that I was 
allocated to; in organizing the study visits according to the timelines and the patients and 
professional’s availability; in identifying the research group of all studies; in applying some 
particular procedures and in providing certain materials. Despite all studies’ documentation being 
organized in the cabinets and despite me having some theoretical knowledge obtained during the 
first year of the Master’s degree, there was a big amount of new information, which I had to 
adapt to. However, when I was not sure of something, I always asked for help in order to clarify 
these doubts. Because we were dealing with people’s lives, it was fundamental to be truly sure of 
all the steps to take. Then, when I had understood the activities and got to the point where I could 
play an active role in the centre, I tried to improve the activities learned. 
The Clinical Trials sub-unit participates in different clinical trials and observational studies. 
Most of them are phase II and phase III clinical trials. This is in line with the overall Portuguese 
trend, as shown by  INFARMED’s statistics (44, 46).  
Due to the high number of phase II and III ongoing clinical trials, I contacted with a wide 
range of procedures to follow. In addition, the several types of visits in each study allowed me to 
manage several facilities and information, as well as to work closely with the different team 
members. Thus, during my training, every day was a challenge. I had the opportunity to contact 
with new things constantly and I learned throughout the whole period. It forced me to grow as a 
person and as a professional, improving my responsibility, time management, self-confidence and 
  
51 
 
teamwork skills. The multidisciplinary specialist approach allowed me to contact with 
neurologists, psychologists, study coordinators, monitors/CRAs, statisticians, laboratory 
technicians, nurses, pharmacists and other professionals that, ensured the conduction of the 
studies. They were always available to share their experience and helped me with their solid 
background in clinical research. This context also provided me with the advantage of increasing 
my network of working contacts.  
The clinical site received protocol amendments several times, and these corresponded to 
updates to the procedures of the clinical trials, implemented as result of the studies’ course or of 
legislative changes. These updates reflect the quickness with which changes happen in the clinical 
research world and how unexpectedly events may occur, even if we work to minimize them.  
In 2016, one man died and four others fell ill during a drug safety study in France (64). The 
case, involving the Portuguese pharmaceutical company Bial, brought to the agenda the issue of 
clinical research. Biotrial, the company’s French CRO partner, was testing a compound called BIA 
10-2474, developed by Bial as a candidate drug for a range of diseases (64). Despite the expert 
panel’s final report, stating that the death of one of the participants in this phase I clinical trial 
was most likely caused by the drug’s toxicity, several inaccuracies, translation mistakes, and 
transcription errors in the documents submitted by the sponsor were also revealed. This 
occurrence alerted the scientific and medical communities to the need for stricter regulation and 
for a higher accuracy in the conduction of clinical trials - “The seriousness of the accident at 
Rennes justifies changes to the regulations and to international best practices” (65). This event 
occurred shortly before I started my training in coordination, which made me think about the 
responsibility of performing all the clinical trial activities and the duty of complying with the 
procedures according to the protocol and the legislation in force. The need for a set of universal, 
stringently enforced guidelines has been reinforced. It was also suggested the creation of an 
international expert panel to continually review best practices and devise protocols in line with 
the most up-to-date information. Furthermore, the official bodies should supervise more the trials 
they approve closely. Greater transparency must also apply to regulators. 
The diversified composition of the research group and the direct contact with the 
stakeholders of a clinical research unit allowed me to learn a lot and improve my communication 
competencies, organisational skills and  the knowledge previously acquired in the Bachelor’s 
degree and in the first year of my Master’s course. It was possible to apply and complement 
concepts learned in the classroom, to learn more due a new perspective (on the job) and to get 
prepared for the real world of clinical research. 
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During almost all my internship, I maintained data management and medical writing 
activities, as result of collaborations in diverse academic projects. These experiences gave me the 
opportunity to improve my communication and research skills. I was also able to complement my 
experience and expand my knowledge in areas like cardiology, clinical pharmacology and 
paediatrics. I had to study each topic carefully, to be able to write on a given subject with 
confidence. Regarding clinical pharmacology, data extraction was initially a difficulty, because I 
had to extract qualitative data that was quite heterogeneous. Presenting results with this data 
was a challenge for me, but at the same time, I developed the ability to synthesize and group 
information. I learned to search in Pubmed/MEDLINE and to construct systematic search 
strategies to find articles on specific themes. Furthermore, I improved my critical analysis skills 
and learned to write a scientific paper rigorously. I also learned how to create an Endnote library 
and to manage my references. This was a very promising learning because it seems to me that it 
will be very useful in the future. To present the statistical results, I learned to manage the SPSS 
software with the help of a statistic technician, as well as to discover new tools for data collection 
in Excel. I learned about some basic concepts on the conduction of a meta-analysis, the type of 
software that was used, and how to interpret the final result (a forest plot). Regarding the 
Cochrane Review Group, despite not having directly collaborated with this sub-unit, it also 
belongs to the LCP structure and I consider the projects developed there to be important. I really 
enjoyed participating in these projects and the contact with senior professionals with lots of 
experience and new ideas was a great source of happiness. I could understand that the interest 
for the practice of evidence-based medicine extended to all professionals working at the unit. 
 I closely monitored an observational study when I trained in the Outcomes sub-unit. This 
experience was very enriching, because I faced, for the first time, the practical hurdles of 
conducting a clinical study. This academic project, ALFABETO, was interesting, because I started to 
collaborate on this project when the first child was recruited. When I received the first CRF to 
update the database, I was faced with some errors and missing data, which in the end would 
decrease the quality of results. Therefore, I had to generate queries and contact the investigators 
in order to clarify the doubts and to give them training about the study and the procedures. 
Because the target population in this study was a paediatric population, the research team should 
adopt a special approach in executing the techniques and in data management. The correct 
training of all the professionals involved was, thus, of maximum importance. 
Chronologically, this direct contact with the monitoring world happened before my 
training in study coordination. I considered that this was a plus in my education, because I 
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understood early the importance of organizing and updating all study documentation and how 
important it is that the CRF is correctly filled. When I started my activity as a study coordinator, I 
was more aware of the importance of communicating with the monitors and of being well trained 
for the entire study procedures. I think my participation as ALFABETO’s monitor was positive 
because I constantly maintained the database updated with new data collected by the 
investigators and I was also in permanent contact with the PI, giving him my opinion about what 
needed to be improved for the success of the study.  
After I collaborated in ALFABETO’s monitoring, I started my internship in UFLVT. A 
research in the literature made me realize that in the last years, there has been a greater 
proximity and interaction between notifiers and the system, contributing to their dissemination 
and for the progressive increase in the annual notification ratio. This increase was the result of 
the growing training of the health professionals and due to the implementation of the Good 
Pharmacovigilance Practices, in 2012. The two months experience at UFLVT was rewarding and 
surprising. The reception and processing of spontaneous notifications requires not only a critical 
eye, but also a good sense of organization. Each notification involves a set of little steps with a 
specific sequence. Initially, it was difficult for me to enter in the unit’s dynamic, but with a few 
days of experience I understood the procedures and I started to analyse each notification 
critically, using my previous knowledge of some basic concepts acquired in the Bachelor’s course 
and during the first year of the Master’s degree. I considered the introductory period a good 
starting point to recall some concepts and procedures related to Pharmacovigilance and Quality 
Assurance and its application to the real work of a regional Pharmacovigilance unit integrated in 
the National Pharmacovigilance System. 
When I did not understand any definition or why things were done in a certain way, I 
always asked UFLVT collaborators for help. I was able to improve my knowledge about some 
medicines and their particularities. Furthermore, I think I became more aware of the risks 
inherent to any drug, which require a cautious and continuous assessment of their safety during 
commercialization. The professionalism of the people who collaborated at the UFLVT was an 
example for me. All the things that happened during their daily activities, including 
correspondence with notifiers and with INFARMED, were registered. When there were doubts 
about any notification or procedures, they quickly discovered the problem and found an efficient 
solution. I was able to take part in the planning of the pharmacovigilance system for clinical trials, 
which made me understand the importance of monitoring the drug safety in a period so 
important and sensible like the clinical trial phases, by reporting all the AEs that may happen 
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during the course of a clinical study. During the time I stayed at the UFLVT, I was also able to 
understand the importance of reporting ADRs, the role of this unit in drug safety control, the need 
for organized and standardized procedures and for quality management. 
My Bachelor’s Degree in Biomedical Sciences and the first year of the Master’s Degree 
were fundamental during this training. They gave me the principal knowledge to work 
consistently in a professional environment. Much of the drug legislation, regulatory guidance, 
ethics documents, anatomy and physiology concepts that I needed to use had already been 
presented to me throughout my previous education. I had to apply these concepts to be able to 
develop my activities in clinical research. This previous knowledge allowed me to quickly adapt 
and to continuously progress throughout the ten months. Obviously, when I arrived at the unit, I 
had to complement this knowledge with specific instructions and practical tips not taught at 
school. For example, I had not received training on processing biological samples, performing 
ECGs and measuring vital signs. These instructions were really important and useful and, in a 
short time, I was able to integrate the group. Since I worked essentially with neurodegenerative 
disorders, I had to apply some concepts about the nervous system, acquired in my Bachelor’s 
degree as well. However, in order to understand the objectives and endpoints of the research 
studies, to help the investigators and enlighten patients’ doubts, I needed to learn more about 
the neurological disorders of the clinical trials I participated in more actively. Namely, I had to 
search for information about FAP, Parkinson’s disease and Huntington’s disease. 
Regarding my participation as study coordinator, I need to mention my pride in working 
full-time in two clinical trials about FAP. FAP was an unknown disease for me until then, and it was 
very interesting to do research work aimed at understanding its particularities and its main 
manifestations. In TTR02 and in ISIS, I followed the participants in many visits. It was rewarding to 
have this experience and to see their improvements, when they apparently felt better, but at the 
same time to have an encouraging word for them when they felt more fragile. It was also 
interesting to discover that FAP was first described in 1952 in a number of families in Portugal 
(66). The most common type of FAP affects about 1 in 500 people in some regions of Northern 
Portugal (66). With the testing of new molecules, such as in these clinical trials, will made possible 
to slow or stop the nerve damage caused by TTR amyloid deposits and to use the body's natural 
processes to lower the levels of TTR protein that cause FAP (53). 
When I started my internship at the Clinical Trials sub-unit, I had been in the other sub-
units for a long period of time, collaborating in medical writing and data management projects 
and in pharmacovigilance activities. The work dynamic as clinical trials’ coordinator was quite 
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different from the previous ones. Therefore, I had some difficulties adapting to the new work 
rhythm, but I easily surpassed them over time. Through my activity as a study coordinator, I 
became more aware of the frequent problems that a Clinical Trials sub-unit can face. I realized 
that, particularly in clinical studies in neurologic diseases, there were some difficulties in 
recruiting patients, with high levels of screening failures observed. I verified that this situation was 
not at all a result of a lack of interest from the research team. Rather, it has been frequently 
associated to the fact that patients have to undergo strict neuropsychological 
scales/questionnaires, where they frequently fail the tight inclusion/exclusion criteria and also 
due to the rigorous design of the study. Development of new medicines in Neurology has also 
been slow because the therapeutic mechanisms are usually complex and there are significant 
economic barriers, when compared to other disease areas (14). I consider that the clinical studies 
in neurodegenerative disorders, like those developed at this unit, are fundamental for the future 
of our society. According to the WHO, one in four individuals will suffer from a mental disorder at 
some point in their life. In the USA, it is estimated that, by 2050, Alzheimer’s disease alone will 
affect up to 16 million Americans, more  5.4 million individuals then today, at an annual care cost 
of US $1.1 trillion (14). 
This internship gave me the opportunity to perform some extra activities, which added to 
my professional skills. The GCP course was an excellent supplement to the knowledge obtained in 
the Bachelor’s and in the Master’s degree. It allowed me to tackle, with more confidence, the 
clinical trial coordination activities of the Clinical Trials sub-unit. The Pharmacovigilance course 
was a good complement for my internship, since shortly thereafter I started my internship at the 
Safety and Drug Utilization Research sub-unit. When I started, I was already elucidated about 
some basic concepts, which facilitated my integration in UFLVT’s daily activities. The Wednesday 
meetings allowed me to understand the importance of rigorous work methodologies and its 
consequences in the quality of results. I also learned from the wide experience of senior 
professionals, since the meetings were always quite casual and discussion was encouraged. The 
Journal club discussions were particularly enlightening, as they highlighted the group’s dynamic 
and different backgrounds, and the prospects that the studies presented could bring to the 
activities of a research centre. Finally, the Risk of Bias Tool Workshop made me realize that there 
are no perfect systematic reviews and that it is of maximum importance to identify the weakest 
points in order to improve in future projects. 
 
  
56 
 
 
  
57 
 
 
4. Conclusion 
 
During my internship at the LCP, I was able to participate in a wide range of activities 
related to clinical studies coordination, as well as data management, medical writing and 
pharmacovigilance. Through these activities, I actively collaborated with different work groups, on 
different projects, and with people with a diverse background and specializations. This allowed 
me to improve my knowledge, learn with experienced professionals and subsequently expand my 
working contacts’ network. 
Despite the majority of the training concerned clinical trial coordination, I had the 
opportunity to collaborate in other projects. Medical writing and pharmacovigilance are examples 
of areas that I also worked in during this period. I participated in projects and studies in different 
neurological disorders – 4 studies in FAP, 2 studies in Huntington's disease, 2 studies in 
Parkinson's disease, one study in Alzheimer's disease and one study Idiopathic Cervical Dystonia. 
Two of them were observational studies and the others were phase II and III clinical trials, each 
for specific indications and with specific requirements. I had to acquire time management and 
organizational skills in order to plan all activities of a day, taking into account that unexpected 
situations can happen. At the same time, I acquired technical knowledge about the pathologies 
and technical procedures. Teamwork is an essential part of the clinical research process. 
Improving this skill was beneficial for me, because I understood that, in practice, we only achieve 
our objectives efficiently if we all work for the same purpose, as a team.  
As a study coordinator trainee, the participation in the daily activities allowed me to 
acquire several skills. In this way, every day, I felt the sense of responsibility. A study coordinator 
must always keep the patient’s safety, the GCP and the ethical principles in mind, as well as the 
need to be compliant with the study protocol. By acting as the bridge between the research staff 
and the sponsor/CRO, this professional allows both entities to provide feedback on each other’s 
activities.  
I enjoyed the interaction with the patients during the internship very much. Each person 
had a different story to tell. I could closely contact with patients and understand their problems, 
fears and difficulties. I contacted most of the time with patients with limiting medical conditions. 
Sometimes it was difficult because I felt the anguish and discouragement of patients. Therefore, 
in addition to the professional learning, I also grew up personally.  
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Despite the fact that clinical trial coordination occupied most of internship time, I need to 
emphasise the monitoring activities. I monitored an observational study in paediatrics that made 
me realise the importance of this position and its inherent difficulties. I think that, in addition to 
being a study coordinator, being a monitor is also interesting. 
The medical writing projects were another challenge that enabled me to improve my 
writing and data management skills. I complemented my ability to search for scientific data, 
organize them and present them in the form of a scientific document. I learned more about 
systematic reviews and meta-analysis, by contacting with experienced professionals.  
The participation in the pharmacovigilance activities of the UFLVT was an excellent 
opportunity to understand the daily routines of the unit and their relevance. During this training 
at the UFLVT, I also understood the importance of quality management and internal organization 
for the success of an institution.  
I enjoyed the training due to the good structure of the host institution, the teamwork 
spirit, the type of activities developed and the contact with the patients. This experience of ten 
months was very rewarding to me because I felt that, directly or indirectly, I was contributing to a 
positive impact in the life of other people. I started to perform clinical research activities and had 
the opportunity to collaborate with a multidisciplinary team with professionals of excellence. I 
could directly contact with patients, which was particularly interesting and made me learn a lot. 
Professionally, I acquired important organizational and methodological tools that I hope will help 
me in the future. Therefore, I conclude that I was able to reach the objectives that I established 
and finished my training successfully. 
In the future, I want to continue my activities in clinical trials coordination and in project 
management.  
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